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And they ask you, [O Muhammad], about 
the soul. Say, "The soul is of the affair of my 
Lord. And mankind have not been given of 
knowledge except a little." Quran 17:85 
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ABSTRACT 
 
Liver disease is a major health problem worldwide. The liver performs a wide range of 
functions, which the human body cannot survive without. The human liver is 
continuously challenged with infectious organisms, alcohol and chemicals, congenital 
defects, autoimmunity and malignancy etc. The liver has been imparted a marvelous 
capacity to regenerate and recover from various insults. However, in many cases liver 
injuries exceed its regenerative capacity with end-stage liver disease becoming the 
inevitable end. 
So far, liver transplantation is still the only treatment modality for end-stage liver 
disease. However, there are many limitations to liver transplantation towards its 
applicability and availability for all patients worldwide, such as scarcity of donors as 
well as other ethical, technical and surgical considerations. 
Cell transplantation is a frequently studied alternative to organ transplantation in liver 
disease. Many cell types are under extensive evaluation, with primary human 
hepatocytes and different stem cell types coming first on the list. For primary human 
hepatocytes, liver tissue is still needed, and when available, cells are produced in huge 
numbers requiring cryopreservation. Available hepatocyte cryopreservation protocols 
still need further optimization. In addition, better cold storage techniques for 
hepatocytes are needed for the feasibility of frequent cell infusions per patient. Stem 
cells still need to be studied further for their differentiation potential towards hepatic 
lineages, safety, immunomodulatory roles, and their possible support for co-
transplanted hepatocytes. 
In this thesis, we addressed a few of the current obstacles facing cellular replacement 
therapy for liver disease. In the first study, we isolated and characterized a 
mesenchymal stem cell population from human fetal liver. The hepatic origin, the 
mesenchymal nature, and the immunomodulatory effects of these cells suggest them as 
potential candidates for cellular therapy for liver disease. In addition, we transplanted 
these cells into a mouse model of liver disease with an evidence for their potential 
differentiation to hepatocyte-like cells in vivo. In the second study, we characterized 
microRNAs expressed in the human liver. Such information can help understanding the 
role of microRNAs in liver development and their potential use in microRNA-based 
stem cell differentiation towards hepatic lineages. In the third study, we introduced a 
new defined xeno-free cryoprotectant to the field of hepatocyte cryopreservation. This 
cryoprotectant could be of value when preserving hepatocytes and stem cell-derived 
hepatocytes in a clinical setting. In the fourth study, we showed that human liver 
material could be better cold-stored as a whole tissue rather than as single cells. This 
makes it possible for frequent hepatocyte infusions commonly needed in a clinical 
context. 
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1 INTRODUCTION 
 
1.1 LIVER DISEASE AND MANAGEMENT OPTIONS 
1.1.1 Global Burden of Chronic Liver Disease 
Cirrhosis is the end stage for many liver diseases. It is characterized by liver fibrosis 
and nodular regeneration. This occurs as a result of a wound-healing response to 
chronic liver injury (Rockey and Friedman 2006). Common causes for cirrhosis are: 
viral infections such as with hepatitis B (HBV) and hepatitis C (HCV) infections, 
alcohol abuse, cholestasis, hepatotoxic drugs, nonalcoholic steatohepatitis (NASH), 
immune-mediated injury and genetic abnormalities. HBV infection is the most 
common cause in developing countries, while alcohol abuse, HCV infection and NASH 
are the most common in developed countries (Guha and Iredale 2007). 
Up to 40% of patients with liver cirrhosis are asymptomatic as cirrhosis is often 
clinically silent (Falagas, Vardakas et al. 2007). This makes it difficult to estimate its 
prevalence and incidence accurately. However, based on autopsy studies, the 
prevalence of liver cirrhosis is 4.5% to 9.5% in the general population, which means 
that hundreds of millions of people are affected worldwide (Graudal, Leth et al. 1991). 
The 5-year mortality in patients with liver failure is 50%; 70% of these are directly 
related to liver disease (Fattovich, Giustina et al. 1997). In 2001, 771,000 patients died 
from cirrhosis, and it was counted as the 14th leading cause of death worldwide 
accounting for 4.4% of all deaths (Mathers, Lopez et al. 2006). In 2020, it is expected 
to rise to the 12th position (Murray and Lopez 1997). 
Chronic liver disease is the most common leading cause to hepatocellular carcinoma 
(HCC) (Fattovich, Stroffolini et al. 2004), which accounts for 70% to 85% of primary 
liver cancers in human (El-Serag 2001). Primary liver cancer represents about 5.6% of 
all human cancers (Parkin, Bray et al. 2001), and is expected to be higher in 2020 
(Murray and Lopez 1997). Liver cancer is rapidly fatal with its incidence-to-mortality 
ratio is almost one (El-Serag 2001). 
 
1.1.2 Current Management Options for Liver Disease 
1.1.2.1 Liver Transplantation 
Orthotopic liver transplantation (OLT) is still the only current treatment modality for 
end-stage liver disease and liver metabolic defects. When successful, the effectiveness 
of OLT is unquestionable. However, OLT has many limitations making the finding of 
other alternatives a necessity. First of all, organ donation has ethical limitations in 
certain communities, and because of high costs, OLT is not affordable in many areas of 
the world. Secondly, lack of donors is a major limitation with around 30% more 
patients on the waiting list than those who actually receive a liver, both in the USA and 
in Europe (Christ and Stock 2012). Also, every year up to 10% die while on the waiting 
list (Strom and Ellis 2011). Finally, OLT is not an ideal treatment for life-threatening 
liver emergencies such as acute liver failure. OLT is a major surgery requiring a 
significant recovery time and with high incidence of surgery related complications. As 
an allogeneic surgery, OLT necessitates lifelong immunosuppression with its own 
complications such as higher incidence of infections and/or malignancies (Perera, 
Mirza et al. 2009). 
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1.1.2.2 Hepatocyte Transplantation 
Hepatocyte transplantation (HT) is not yet an established treatment option for liver 
disease, but is under extensive investigation. Compared to OLT, HT is a less costly and 
less invasive procedure with shorter recovery periods and fewer complications. 
Keeping the native liver makes HT an ideal treatment option for metabolic liver disease 
with otherwise stable liver functions where hepatocytes can be used directly or after 
genetic modification (Birraux, Wildhaber et al. 2010). Successfully cryopreserved 
hepatocytes make HT a true option for cell therapy for acute liver failure (Fitzpatrick, 
Mitry et al. 2009). HT has gained proof-of-concept in more than 30 clinical trials where 
a repopulation of 1-5% was able to correct, at least transiently, defects in liver function 
bridging patients to OLT (Fox, Chowdhury et al. 1998; Hughes, Mitry et al. 2012). 
Nevertheless, liver donation and immunosuppression are still needed in HT. Since there 
is no strong evidence suggesting a lifelong efficacy for HT in humans, other sources for 
hepatocytes such as xenotransplants (Nagata, Ito et al. 2003), immortalized hepatocytes 
(Kobayashi, Fujiwara et al. 2000), and stem cell-derived hepatocytes (Chen, Tseng et 
al. 2012) should be perused. However, a fully optimized hepatocyte cryopreservation 
protocol is still lacking for all these treatment options. 
 
1.1.2.3 Bioartificial Extracorporeal Liver Support System 
It has been shown that many of the essential metabolic functions of the liver such as 
protein synthesis, urea production, conjugation, and detoxification might be provided 
by isolated hepatocytes (Yarmush, Dunn et al. 1992). Extracorporeal liver support 
systems are an experimental treatment option aiming at providing cellular support for 
the liver in e.g. acute liver failure. Similar to a hemodialysis device, an extracorporeal 
liver support system is composed of a bioreactor containing numerous hollow fibers of 
semipermeable membranes loaded with human or porcine hepatocytes and perfused 
with patient’s plasma or blood (Sgroi, Serre-Beinier et al. 2009).  
 
1.2 LIVER STRUCTURE AND FUNCTION 
1.2.1 Liver Structure 
Liver is the largest gland in the body constituting around 2% of the adult body weight. 
Anatomically, the liver is composed of a parenchyma and stroma with parenchymal and 
non-parenchymal cells as well as vascular and biliary trees. The parenchyma comprises 
hepatocytes constituting the main part of the hepatic lobule. The non-parenchymal cells 
are mainly sinusoidal endothelial cells, Kupffer cells, stellate cells, dendritic cells and 
biliary epithelial cells. The liver tissue volume is composed as follows; 78% 
hepatocytes, 2.8% sinusoidal endothelial cells, 2.1% Kupffer cells, 1.4% hepatic 
stellate cells, with the extracellular space representing 16% (Gumucio, Berkovitz et al. 
1996). 
The hepatic lobule is the basic structural unit of the liver (Rappaport, Borowy et al. 
1954). It has a characteristic hexagonal shape with liver cell plates radiating from the 
portal triads in the corners towards a central vein in the middle (figure 2.1). The liver 
cell plates are one-cell-thick hepatocyte cords. The hepatocyte plates pound hepatic 
sinusoids, which are lined by fenestrated sinusoidal endothelial cells. A portal triad 
contains interwoven branches of a portal vein, a hepatic artery and a bile duct. Blood 
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Figure 2.1: Microanatomy of a hepatic lobule. Hepatocytes are arranged in cords and are separated by 
hepatic sinusoids. Blood flows peripherally from the portal tract to the central vein through the 
sinusoids. The portal tract contains a branch of hepatic artery, a branch of portal vein and a bile duct. 
Illustrated by Mohammed Saliem.
flows from both the portal vein and hepatic artery through the sinusoids ending in the 
central vein. The portal blood, coming mainly from the intestine, is rich in nutrients 
while the hepatic artery carries blood rich in oxygen (Ishibashi, Nakamura et al. 2009; 
Abdel-Misih and Bloomston 2010). 
The hepatocytes are polarized epithelial cells. They perform their metabolic and 
endocrine functions through their basolateral surfaces across the fenestrated sinusoidal 
endothelium. Neighboring hepatocytes are interconnected with tight junctions 
circumscribing bile canaliculi facing the apical surface of the hepatocytes and through 
them hepatocytes perform their exocrine function, bile secretion (Si-Tayeb, Lemaigre et 
al. 2010). 
Kupffer cells are resident liver tissue macrophages. They reside inside the sinusoids 
within gaps between the endothelial cells. They constitute the largest population of 
macrophages in the body and migrate to the site of injury within the liver (Ishibashi, 
Nakamura et al. 2009; Abdel-Misih and Bloomston 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hepatic stellate cells reside in the perisinusoidal space of Disse and their main function 
is vitamin A storage. Upon liver injury, hepatic stellate cells transform into 
myofibroblasts producing extracellular matrix. As a result they play an important role 
in progression of fibrosis (Ishibashi, Nakamura et al. 2009; Abdel-Misih and 
Bloomston 2010). 
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1.2.2 Liver Function 
Liver is a gland performing both exocrine and endocrine functions. The major exocrine 
function is bile secretion, which is essential for the absorption of fat and lipophilic 
nutrients. The endocrine functions are mainly secretion of many essential hormones e.g. 
thrombopoietin, angiotensinogen and insulin-like growth factor. The liver receives 
nutrients and transforms them into secreted proteins. Examples for these proteins are 
albumin, most of the clotting factors, the majority of plasma carrier proteins and 
apolipoproteins. The liver has also an essential role in drug metabolism and 
detoxification. The liver performs and controls many other metabolic processes such as 
glycogen storage, cholesterol synthesis and transport, as well as urea secretion and 
metabolism (Corless and Middleton 1983; Si-Tayeb, Lemaigre et al. 2010).  
The fetal liver transiently also exhibits hematopoietic functions becoming the principle 
hematopoietic organ early in development. Hepatic progenitors and fetal liver stromal 
cells have been shown to support hematopoiesis in vitro (Hata, Nanno et al. 1993) 
(Martin and Bhatia 2005). On the other hand, differentiated hepatic progenitor cells did 
not support hematopoiesis (Kinoshita, Sekiguchi et al. 1999). Furthermore, 
hematopoietic cells from fetal liver expressed oncostatin M (OSM), which has been 
shown to enhance hepatocyte differentiation (Yoshimura, Ichihara et al. 1996). 
Together, these data suggest a dynamic interplay between hematopoietic, parenchymal 
and stromal cells within the developing fetal liver, controlling both hematopoiesis and 
hepatogenesis. 
 
1.3 LIVER DEVELOPMENT 
1.3.1  Competence, Induction and Specification 
Upon gastrulation, three germ layers form: ectoderm, mesoderm and endoderm. The 
liver develops from the ventral part of the definitive endoderm delineating the primitive 
foregut. A crosstalk between three major neighboring areas is needed for proper 
development of the liver, one endodermal and two mesodermal: the gut endoderm, 
cardiogenic mesoderm and septum transversum mesenchyme (Tremblay and Zaret 
2005) (figure 2.2A). 
A widely accepted model for liver development begins when a certain group of 
endoderm cells gains ‘competence’ to differentiate toward hepatic lineages. 
‘Competent’ endoderm cells are not specified yet, but gain the capacity to respond to 
liver specification-induction signals. Competence occurs when these cells start to 
express certain transcription factors, mainly forkhead box (FOX) A and GATA-binding 
protein 4 (GATA4) factors (Bossard and Zaret 1998). The expression of FOXA factors 
in the endoderm cells is depended, in turn,  on their expression of hepatocyte nuclear 
factor (HNF) 1 (Lokmane, Haumaitre et al. 2008). 
The next step in liver development is ‘specification’ where ‘competent’ endoderm cells 
start to respond to extracellular inducers specifying them to the hepatic fate (figure 
2.2B). The first molecular evidence for hepatic specification is the expression of 
albumin, -fetoprotein and transthyretin (Jung, Zheng et al. 1999). The first inducers to 
be identified are fibroblast growth factors (FGFs) originating from the cardiogenic 
mesoderm (Zaret 2008). A gradient concentration of FGFs is established and ‘low’ 
levels are crucial for the induction of hepatic genes. Later when more FGFs are 
produced by the cardiogenic mesoderm, their ‘low’ concentration in the hepatic domain 
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Figure 2.2: Liver development in human. An interaction between foregut endoderm, septum 
transversum mesenchyme and cardiogenic mesoderm is needed. Foregut endoderm first gains 
competence to develop to liver (A) and then becomes specified to liver fate (B). Hepatoblasts 
develop from specified endoderm and migrate into septum transversum mesenchyme (C). Hepatic 
diverticulum forms and developing liver buds into septum transversum mesenchyme (D). Bile duct 
formation starts with ductal plate development into asymmetric duct with hepatoblasts constituting 
part of its wall then matures by having only cholangiocytes in its wall (E&F). Illustrated by 
Mohammed Saliem. 
is maintained by specific spatial changes. The septum transversum grows intervening 
between the cardiogenic mesoderm and the pre-hepatic endoderm (Serls, Doherty et al. 
2005). FGFs mediate their hepatic induction through the mitogen-activated protein 
kinase (MAPK) signaling pathway (Calmont, Wandzioch et al. 2006). In addition to 
FGFs, bone morphogenetic proteins (BMPs) from the septum transversum 
mesenchyme contribute to hepatic-specific gene induction, probably through 
stimulation of GATA4 expression (Shin, Shin et al. 2007). It has been shown that Wnt 
signaling also has an important role in hepatic induction. Early in development, 
repression of Wnt signaling anteriorly by endoderm is crucial for maintaining foregut 
identity and for allowing for liver development. 
 
1.3.2 Formation of the Hepatic Bud 
 
The first gross morphological event in human liver development is formation of hepatic 
diverticulum by day 22 (figure 2.2C&D). ‘Competent’ endoderm cells, now called 
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hepatoblasts, bud into the surrounding septum transversum mesenchyme. Hepatoblasts 
are first columnar, and then become pseudostratified epithelium (Martinez Barbera, 
Clements et al. 2000). Hepatoblasts face a basement membrane, which separates them 
from an endothelial cell layer (figure 2.2C). The basement membrane contains 
fibronectin, laminin, collagen IV, nidogen and heparan sulfate proteoglycan (Bort, 
Signore et al. 2006). 
A symphony of complex cellular events is involved in the formation of the hepatic bud. 
This includes cellular proliferation, migration, adhesion and differentiation. For 
migration, developing hepatoblasts undergo transient epithelial-mesenchymal transition 
and downregulation of E-cadherin expression. The homeobox (Hex) factor, GATA6, 
HNF6, Onecut (OC) 2, T-box transcription factor 3 (Tbx3), prospero-related 
homeobox-1 (Prox1) have been all shown to be involved in hepatoblast migration and 
adhesion (Lemaigre 2009). 
 
1.3.3 Expansion of the Liver 
Continuous interactions between hepatoblasts and adjacent mesodermal, endothelial 
and mesenchymal cells are necessary for the expansion of the liver and several growth 
factors are involved. Hepatocyte growth factor (HGF) is secreted by the septum 
transversum mesenchyme, the endothelial cells and the hepatoblasts. HGF acting on its 
receptor c-met on the hepatoblasts stimulates the SEK1/MKK4 pathway contributing to 
hepatoblast proliferation and liver expansion (Nishina, Vaz et al. 1999). The 
transforming growth factor (TGF) β-Smad2/Smad3 signaling pathway also is involved 
(Weinstein, Monga et al. 2001). Hepatoma-derived growth factor (HDGF) appears to 
stimulate proliferation of hepatoblasts in vitro; however this lacks an in vivo evidence 
suggesting unknown compensatory mechanisms to be involved (Gallitzendoerfer, 
Abouzied et al. 2008). It has also been shown that Wnt ligands, e.g. Wnt9, and their 
Frizzled receptors mediate hepatoblast proliferation (Matsumoto, Miki et al. 2008). 
Wnt signaling pathway, and its canonical mediator β-catenin, may help in achieving 
global liver morphology through localized control of hepatic cell proliferation creating 
localized growth zones in the liver (Suksaweang, Lin et al. 2004). Mesenchymal stem 
cells (MSCs) intermingled with hepatoblasts have been shown to stimulate hepatoblast 
proliferation by secreting hepatotrophic factors. The production of these trophic factors 
may be mediated by retinoic acid and its receptor RXR expressed in MSCs. In 
addition to its indirect effect on hepatoblast proliferation, retinoic acid may also affect 
liver lobulation and global morphology (Ijpenberg, Perez-Pomares et al. 2007). Proper 
liver expansion is not only dependent on the stimulation and regional control of 
hepatoblast proliferation, but also on prevention of their apoptosis. It has been shown 
that expression of the transcription factor nuclear factor B (NFB) protects against 
apoptosis mediated by tumor necrosis factor (TNF) (Doi, Marino et al. 1999). 
 
1.3.4 Fate Decision of Liver Cells 
Cell fate decisions during liver development refer mainly to the commitment of 
hepatoblasts either to hepatocyte lineage or cholangiocyte lineage. However, it is also 
noteworthy to consider the development of other cellular components in the liver: 
vascular and sinusoidal endothelial cells, stellate cells and Kupffer cells. Cell fate 
decision during liver development is still not fully explained. 
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Explaining hepatobiliary lineage commitment is depended on the identification of 
hepatocyte- and cholangiocyte-specific markers. Many of these lineage-specific 
markers are expressed, to a lesser extent, in the other lineage or in the definitive 
endoderm. For example, the cholangiocyte-specific cytoskeletal (CK) proteins 7 and 19 
are not the best indicators for biliary cell fate decision. For CK7, it is only detectable 
when the biliary cell fate decision has been already established. CK19 is also expressed 
in hepatocytes, albeit to a lesser degree (Van Eyken, Sciot et al. 1988). However, 
expression of the transcription factor hepatocyte nuclear factor 4 (HNF4) is 
considered mandatory for hepatocyte commitment (Li, Ning et al. 2000). Similarly, the 
re-expression of the SRY-related HMG box transcription factor 9 (SOX9) is considered 
necessary for cholangiocyte commitment (Antoniou, Raynaud et al. 2009). There is 
some evidence indicating a role for Tbx3 (Ludtke, Christoffels et al. 2009) and HNF6 
(Clotman, Lannoy et al. 2002) in the timing of hepatoblast fate decision, by promoting 
their biliary differentiation. TGFβ (Clotman, Jacquemin et al. 2005), Jagged-Notch 
(Tanimizu and Miyajima 2004), Wnt/β-catenin (Hussain, Sneddon et al. 2004), FGF2/7 
(Yanai, Tatsumi et al. 2008), BMP4 (Ader, Norel et al. 2006) have potential roles in 
biliary differentiation and hepatoblast fate decisions. On the other hand, HGF promotes 
hepatocyte differentiation by stimulating the expression of the transcription factor 
CCAAT enhancer binding protein α (C/EBPα) (Suzuki, Iwama et al. 2003). Whether 
different extracellular matrix components influence hepatoblast fate determination still 
needs further evaluation after these controversial data. 
Sinusoidal endothelial cells express the vascular adhesion molecule-1 (VAP1), stabilin 
1 and 2, L-SIGN, reelm and have low expression of CD31 and von Willibrand factor, 
but do not express CD34 (type 1 transmembrane sialomucin), which is regularly 
expressed in other endothelial cell types (Nonaka, Tanaka et al. 2007). Also, they share 
expression of the lymphatic vascular endothelial hyaluronan receptor-1 (LYVE1) with 
lymphatic endothelial cells (Mouta Carreira, Nasser et al. 2001). 
Hepatic stellate cells may have a mesothelial, rather than endodermal or mesenchymal 
origin. There is some evidence for a potential role for Wilm’s Tumor (Wt1) and 
retinoic acid in the development of hepatic stellate cells (Ijpenberg, Perez-Pomares et 
al. 2007). Hepatic cells expressing the activated leukocyte cell adhesion molecule 
(ALCAM) have similar features to hepatic stellate cells (Loo and Wu 2008). 
 
1.3.5 Development of Hepatic Vasculature 
During liver development, new blood vessels form either de novo (vasculogenesis) or 
sprout out from preexisting vessels (angiogenesis). Hepatic sinusoids are the first part 
of the hepatic vascular network to develop. They form by angiogenesis from vessels of 
the septum transversum mesenchyme (Collardeau-Frachon and Scoazec 2008). There is 
some evidence for involvement of vasculogenesis with the formation of new 
endothelial cells of mesothelial origin (Perez-Pomares, Carmona et al. 2004). Hepatic 
sinusoids gradually mature both anatomically and functionally as their endothelial cells 
mature probably as a result of changes in extracellular matrix composition with 
development (Nonaka, Tanaka et al. 2007).  
The efferent venous system of the fetal liver develops from the vitelline veins. The 
major efferent venous supply to the fetal liver comes from the umbilical vein. The 
portal vein replaces the umbilical vein after birth (Collardeau-Frachon and Scoazec 
2008). The hepatic artery develops after the venous system along the intrahepatic portal 
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vein and gradually extends to the periphery (Gouysse, Couvelard et al. 2002). It has 
been postulated that development of the intrahepatic arterial system is directed by the 
developing ductal plate (see below) and its secreted vascular endothelial growth factor 
(VEGF) (Clotman, Libbrecht et al. 2003). 
The intrahepatic bile ducts are formed by cholangiocytes developing from hepatoblasts. 
Cholangiocyte differentiation is stimulated by TGF signaling with higher ligand 
concentration closer to portal branches (Antoniou, Raynaud et al. 2009). There is some 
evidence suggesting the involvement also of Notch signaling in cholangiocyte 
development (McDaniell, Warthen et al. 2006). Notch signaling may help restrict 
cholangiocyte differentiation to periportal hepatoblasts (Zong, Panikkar et al. 2009). In 
addition to TGF and Notch, other signaling pathways have been suggested to 
contribute to cholangiocyte differentiation like Wnt (Decaens, Godard et al. 2008) as 
well as FGF and BMP (Yanai, Tatsumi et al. 2008). Cholangiocytes first arrange 
themselves as a monolayer ring called the ductal plate along the intrahepatic portal 
branches. A second layer of hepatoblasts arranges itself closer to the parenchymal side 
of the primary cholangiocyte layer separated by a luminal space and creating an 
asymmetrical ductal structure (figure 2.2E). This asymmetrical structure is transient as 
the second hepatoblast layer differentiates to cholangiocytes in a second wave of 
cholangiocyte development (figure 2.2F). In addition to their role in cholangiocyte 
differentiation, both Notch and TGF- signaling pathways are instrumental in biliary 
duct formation (Antoniou, Raynaud et al. 2009). Similarly, several transcription factors 
are involved in both processes such as HNF1 (Coffinier, Gresh et al. 2002); HNF6 
and Onecut2 (Clotman, Lannoy et al. 2002); as well as C/EBP (Yamasaki, Sada et al. 
2006) and Hhex (Hunter, Wilson et al. 2007). Towards the end of gestation, when 
cholangiocyte differentiation and duct symmetry are accomplished, cholangiocyte 
multiplication continues to add to biliary duct growth. 
 
1.3.6 Hepatocyte Maturation 
After hepatoblast fate determination, developing hepatocytes undergo maturation where 
the hepatocytes gradually acquire their characteristic morphology and functions. 
Hepatocyte maturation is a continuous process extending even to the neonatal period. 
Jaundice appears normally in neonates sometimes due to a physiological delay in the 
ability of hepatocytes to conjugate bilirubin (Kaniwa, Kurose et al. 2005). Maturation is 
effected by a dynamic transcriptional network with progressive increase in complexity 
(Petkov, Zavadil et al. 2004). Several liver-enriched factors such as HNF1α, HNF1β, 
FoxA2, HNF4α1, HNF6 and Liver receptor homolog-1 (LRH1) showed synergistic 
interdependence where they are able to mutually control each other and to cooperate 
with other factors in stimulating target gene expression (Kyrmizi, Hatzis et al. 2006). 
The progressive increase in concentration of these factors and the interplay between 
them throughout the maturation process may help activate liver-specific genes at 
certain time points during different developmental stages. 
Several studies have linked many of the liver-enriched factors to certain liver functions. 
For example, HNF1α/4α were linked to glucose, lipid and amino acid metabolism 
(Odom, Zizlsperger et al. 2004); HNF1β to bile acid sensing and fatty acid oxidation 
(Coffinier, Gresh et al. 2002); HNF6 to growth hormone (Lahuna, Fernandez et al. 
1997) and glucocorticoid activity (Pierreux, Stafford et al. 1999); LRH1 to bile acid 
and cholesterol metabolism (Lee and Moore 2008); C/EBPα to glucose, glycogen and 
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lipid metabolism and hepatocyte proliferation and C/EBPβ to gluconeogenesis 
(Lekstrom-Himes and Xanthopoulos 1998). 
Gene expression is the main process involved in hepatocyte maturation. However, 
some genes need to be repressed for maturation to take place. For example, the 
proliferation factor hepatoma-derived growth factor (HDGF) is downregulated later in 
liver development (Enomoto, Yoshida et al. 2002). Similarly, α-fetoprotein is 
downregulated in adult liver when its gene is repressed by for example the zinc finger 
and homeoboxes factor 2 (zhx2) (Perincheri, Dingle et al. 2005) or the Zinc finger 
factor, zinc finger and BTB domain containing 20 (ZBTB20) (Xie, Zhang et al. 2008). 
It is noteworthy to mention that both zhx2 and ZBTB20 are not liver-specific proteins 
exerting liver-specific functions. 
In addition to zhx2 and ZBTB20, oncostatin M (OSM) is necessary for hepatocyte 
maturation while coming from a non-hepatic origin. OSM is an interleukin-6-related 
cytokine secreted by hematopoietic cells abundantly available in the developing liver 
being the first hematopoietic organ in the body. OSM stimulated the expression of 
terminal hepatocyte differentiation markers through binding to gp130 receptor initiating 
a STAT3-mediated signaling cascade (Ito, Matsui et al. 2000). The transcription factor 
Jumonji also mediates OSM activity (Anzai, Kamiya et al. 2003).  
The achievement of the characteristic cord-like arrangement of hepatocytes is effected 
by the guanosine triphosphatase adenosine diphosphate-ribosylation factor 6 (ARF6), 
which seems to be dependent on HGF in its function (Suzuki, Kanai et al. 2006). There 
is some evidence for a role for sinusoidal endothelial cells in establishing the apico-
basal polarity in hepatocytes (Sakaguchi, Sadler et al. 2008). HGF is essential for 
hepatocyte maturation exerting its effects, similar to OSM, mainly postnatal as 
suggested from its higher neonatal levels (Kamiya, Kinoshita et al. 2001).  
Hepatocytes undergo metabolic zonation where hepatocytes at different locations in the 
hepatic lobule have different metabolic functions. Hepatocytes are thus a heterogeneous 
cell population expressing different sets of genes between the periportal and the 
pericentral zones (Jungermann and Katz 1989). For example, glutamine synthetase, 
ornithine aminotransferase and thyroid hormone receptor β are exclusively expressed in 
the pericentral zone. There is some evidence indicating that periportal repression of 
glutamine synthetase is effected by histone deacetylase type I recruited by HNF4α 
(Stanulovic, Kyrmizi et al. 2007). Another example is the complementary expression of 
β-catenin and its repressor adenomatous polyposis coli protein (APC). APC is 
considered as the key regulator of lobular zonation. For APC being expressed periportal 
prevents pericentrally-expressed β-catenin from being expressed also periportal thus 
ensuring the periportal and pericentral gene expression patterns (Benhamouche, 
Decaens et al. 2006). 
The metabolic zonation events take place mainly after birth (Jungermann and Katz 
1989) reflecting the importance of the postnatal period in hepatocyte maturation. This 
is best illustrated by the ontogeny of liver drug metabolizing enzymes (DMEs), mainly 
the cytochrome P450 enzymes (CYPs) (See below). 
 
1.3.7 Ontogeny of Liver Drug Metabolizing Enzymes 
DME ontogeny refers to the time-wise expression of different DMEs during liver 
development (table 2.1). Although human liver starts to develop as early as the 4th week 
of gestation, it is not before the 8th-10th weeks when the first DME activities are 
detected (Stevens, Hines et al. 2003). DMEs (Hines 2008; Hart, Cui et al. 2009) can be 
divided into 2 major groups: oxidative and conjugation enzymes. The oxidative group 
contains 5 major families: alcohol dehydrogenases (ADHs), aldehyde oxidases 
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(AOXs), CYPs, flavin-containing monooxygenases (FMOs) and paroxonases (PONs). 
The conjugation group contains 4 major families: epoxide hydrolases (EPHXs), 
glutathione S-transferases (GSTAs), sulfotransferases (SLUTs) and uridine 5'-
diphosphoglucuronic acid (UDP) glucuronosyltransferases (UGTs). 
ADHs include 7 major enzymes: ADH1A, -1B, -1C, ADH4, ADH5, ADH6, ADH7. 
ADHs catalyze oxidation of alcohols and reduction of aldehydes. ADH1 enzymes 
catalyze ethanol oxidation (Edenberg and Bosron 1997). 
AOXs include 2 members AOX1 and AOX2. AOXs have important roles in 
metabolism of aldehyde-containing and N-heterocyclic drugs and xenobiotics. CYPs 
include 59 members belonging to 18 families and 42 subfamilies. CYP1-3 families 
alone include 23 enzymes and carry on the majority of drug and toxicant metabolism. 
CYP1 family has 3 major members CYP1A1, -1A2 and -1B1. CYP2 family has 4 
major subfamilies: CYP2A containing mainly CYP2A6, -2A7 and -2A13: CYP2C 
containing mainly CYP2C8, -2C9, -2C18 and -2C19: CYP2D6: and CYP2E1. CYP3 
family includes mainly the CYP3A subfamily, which contains mainly CYP3A4, -3A5, 
-3A7 and -3A43 (Hines 2008). 
CYP2C family constitutes 18% of CYPs in adult liver (Shimada, Yamazaki et al. 
1994). They are responsible for around 29% of oxidative metabolism of clinically 
relevant drugs e.g. warfarin, phenytoin, diclofenac, ibuprofen, omeprazole and losartan 
(Williams, Hyland et al. 2004). CYP2D6 constitutes less than 2% of adult liver CYPs 
(Shimada, Yamazaki et al. 1994). It is responsible for oxidative metabolism of 12% of 
clinically relevant drugs e.g. atomoxetine as well as o-demethylation of codeine to 
morphine and of dextromethorphan to dextrorphan. CYP2E1 constitutes 7% of adult 
liver CYPs (Shimada, Yamazaki et al. 1994). It is responsible for oxidative metabolism 
of 2.5% of clinically relevant drugs e.g. acetaminophen, halothane and chlorzoxazone 
(Williams, Hyland et al. 2004) and bioactivation of e.g. ethanol, benzene and toluene 
(Tanaka, Terada et al. 2000). 
CYP3A4, CYP3A5 and CYP3A7 are the most abundant liver CYPs while CYP3A34 is 
the least important isoform. They are responsible for oxidative metabolism of 46% of 
clinically-relevant drugs (Williams, Hyland et al. 2004). CYP3A4, alone, accounts for 
10-50% of adult liver CYPs (Shimada, Yamazaki et al. 1994). CYP3A5 can exceed 
CYP3A4, depending on the presence of CYP3A5*1 allele) (Lin, Dowling et al. 2002). 
CYP3A7 is the dominant CYP3A isoform in fetal liver and accounts for 10-40% of 
adult CYPs, depending on the presence of 3A7*1C allele (Sim, Edwards et al. 2005). 
FMO family includes 11 members FMO1-5 and 6P-11P. FMO1, FMO2 and FMO3 
showed xenobiotic metabolic activities for e.g. tamoxifen, itopride, benzydamine, 
olopatidine and xanomeline (Krueger and Williams 2005). 
PON1 is involved in metabolism and clearance of oxidized lipids (Durrington, 
Mackness et al. 2001) and some organophosphorous compounds e.g. soman, sarin and 
diazoxon (Costa, Li et al. 1999). 
EPHXs exist mainly in 2 forms; microsomal (EPHX1) and soluble (EPHX2). EPHXs 
detoxify highly reactive xenobiotic epoxides (cyclic ethers) by adding water 
(hydrolase) to form dihydrodiols (Morisseau and Hammock 2005). 
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Enzyme Ontogeny Activity/Expression	
ADH1A Week 13.5 Dominant fetal form of ADH1s until week 36  
ADH1B Week 16 10% of adult values 
ADH1C Week 19 10% of adult values 
AOXs Neonatal 10-15% of adult values 
CYP1A1 Week 7 Occasional expression in the adult  
CYP1A2 Neonatal 4-5% of adult values 
CYP2A6 Week 17 postnatal Higher in the adult 
CYP2C9 Weeks 8-22 1% adult values 
CYP2C19 Weeks 12-40 10-20% of adult values 
CYP2D6 Weeks 25-30 5% of adult values (in 30% of samples) 
CYP2E1 Perinatal 10% of adult values (neonatal) 
CYP3A7 Weeks 6-12 Mainly fetal (100-fold>CYP3A4) 
CYP3A4 Weeks 7-17 10% of adult values (before week 30) 
CYP3A5 Weeks 6-12 No age-related change 
FMO1 Weeks 8-15 Mainly fetal 
FMO3 First trimester (15% of 
samples) 
Reaches adult values by year 18 
PON1 Neonatal Reaches a plateau 10-25 months postnatal 
EPHX1 Weeks 7.6-21.9 50% of adult values 
EPHX2 Weeks 14-27 20% of adult values 
GSTM Weeks 14-25 2.5-16.5% of total GST activity 
GSTA Weeks 14-25 45-90% of total GST activity 
GSTP Weeks 14-25 Mainly fetal (30-50% of total GST activity) 
SULT1A1 Weeks 14-27 Fixed levels until 12 month postnatal 
SULT1A3 Weeks 10-22 10-fold reduction postnatal  
SULT1E1 First trimester Progressive reduction afterwards 
SULT1C2 Prenatal Higher in adult 
SULT2A1 Weeks 8-40 Reaches a plateau 3 months postnatal 
UGT1A1 Months 3-6 postnatal Adult values 
UGT1A3 Prenatal 30% of adult values 
UGT1A6 Prenatal 1-10% of adult values 
UGT2B7 Weeks 15-27 10-20% of adult values 
UGT2B17 Prenatal <10% of adult values 
 
 
 
 
 
GSTs have three families cytosolic, microsomal and mitochondrial. GSTs help detoxify 
hydrophobic xenobiotics (containing carbon, nitrogen or sulfur atoms) by catalyzing 
the attacking by reduced glutathione. Cytosolic GSTs are considered as the most 
important among all GSTs for their role in drug and toxicant metabolism (Hayes, 
Table 2.1: Ontogeny of the most common hepatic drug metabolizing enzymes 
(DMEs). Summarized from (Hines 2008; Hart, Cui et al. 2009). 
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Flanagan et al. 2005). Cytosolic GSTs include 16 members distributed into 6 
subfamilies; GSTA (alpha), GSTM (mu), GSTO (omega), GSTP (pi), GSTT (theta) 
and GSTZ (zeta) (Nebert and Vasiliou 2004). 
SULTs include 3 families, phenol SULTs (SULT1), hydroxysteroid SULTs (SULT2) 
and brain-specific SULT (SULT4). SULT1s include 4 subfamilies with 7 members; 
SULT1A1, -1A2, -1A3/4, -1B1, -1C2, -1C4 and -1E1. SULT2s have 2 subfamilies 
with 2 members; SULT2A1 and -2B1. SULT4 subfamily has only one member; 
SULT4A1 (Blanchard, Freimuth et al. 2004). 
UGTs include 2 families with 16 genes. UGT1 family has 9 members; UGT1A1, -1A3, 
-1A4, -1A5, -1A6, -1A7, -1A8, -1A9 and -1A10 (Tukey and Strassburg 2000). 
UGT1A1 is responsible for bilirubin glucuronidation (de Wildt, Kearns et al. 1999).  
UGT2 family has 7 members; UGT2A1, -2B4, -2B7, -2B10, -2B11, -2B15 and -2B17 
(Tukey and Strassburg 2000). UGT2B7 is responsible for morphine glucuronidation 
(de Wildt, Kearns et al. 1999). 
 
1.4 MICRORNAS 
1.4.1 History and Formation 
MicroRNAs (miRNAs) are the most abundant among the three major classes of small 
RNAs; miRNAs, small-interfering RNAs and Piwi-interacting RNAs. The first miRNA 
to be discovered was lin4 in Caenorhabditis elegans in 1993 (Lee, Feinbaum et al. 
1993; Wightman, Ha et al. 1993). Lin4 was discovered as a short non-protein coding 
transcript that was able to regulate the lin14 gene post-transcriptionally through its 3´ 
untranslated region (UTR). Seven years later, the miRNA let7 was discovered in a 
similar way to lin4 (Reinhart, Slack et al. 2000) and was found to be evolutionary 
conserved from insects to humans (Pasquinelli, Reinhart et al. 2000). This breakthrough 
triggered a revolution in miRNAs research, which began with the discovery of the let7 
family that share the same sequence identity with let7 called ‘seed’ areas and have, as a 
result, similar mRNA targets (Kaufman and Miska 2010). Today, thousands of 
miRNAs have been discovered in humans and many other species, and their potential 
roles in health and disease are being unraveled. 
miRNAs are first synthesized within the nucleus by RNA polymerase II/III as primary 
(pri)-miRNAs (Lee, Kim et al. 2004; Borchert, Lanier et al. 2006) (figure 2.3). Pri-
miRNAs are long transcripts with a cap at the 5´end and a poly-adenine tail at the 
3´end. Pri-miRNAs are processed by the nuclear Microprocessor complex, which 
contains RNase III Drosha and DGCR8/Pasha proteins, to produce precursor (pre)-
miRNAs of 60-110 nucleotides in length. With the help of Exportin 5, Pre-miRNAs are 
exported to the cytoplasm to be processed further by RNase III Dicer-1 together with 
TRBP/PACT protein. The outproduct is imperfect double-stranded duplexes that need 
to be unwounded by helicase to form mature single-stranded miRNAs (Siomi and 
Siomi 2010). 
Mature miRNAs are small RNAs of about 20-24 nucleotides in length. They work on 
the post-transcriptional level to regulate gene expression, using mechanisms which are 
not fully explained. What is known is that they bind to certain RNA-induced silencing 
complexes (RISCs) and guide them towards targeted genetic messages with fully or 
partially complementary sequences mainly in their 3´ UTRs (Brodersen and Voinnet 
2009). The targeted messages are commonly repressed as a result of the miRNA-RISC 
action. It is not clearly understood how the repression happens but possible 
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explanations are; inhibition of mRNA translation into protein, accelerated mRNA 
decay or site-specific slicing in miRNA-mRNA pairs (Eulalio, Huntzinger et al. 2008). 
miRNAs use imperfect Watson-Crick base-pairing for mRNA target recognition. 
Nucleotides 2-7, called the ‘seed’ of miRNAs, are of special importance. Imperfect 
miRNA-mRNA hybrids with central bulges result in either translational inhibition or 
exonucleolytic mRNA decay, while highly complementary hybrids with central pairing 
result in mRNA slicing (Brodersen and Voinnet 2009). 
The regulatory output of miRNA-mRNA interactions is dependent on many factors. 
The most important factors are: the complementary sites in targeted messages and the 
degree of their complementarity especially for the ‘seed’ regions; complementary site 
multiplicity; target site accessibility; the relative in vivo concentration of miRNAs to 
their target mRNAs; and the type of RISCs or Ago proteins on which miRNAs are 
loaded. Target site accessibility can be influenced by the presence of stable RNA 
secondary structures or RNA-binding proteins (Brodersen and Voinnet 2009). 
 
 
  
 
 
 
 
 
Figure 2.3: MicroRNA (miRNA) formation. miRNAs are transcribed in the nucleus as pri-miRNAs 
that are cleaved by Drosha to form pre-miRNAs, which are then exported to the cytoplasm and finally 
processed by Dicer producing mature miRNAs. Mature miRNAs bind to RISCs to modulate mRNA 
translation. Illustrated by Mohammed Saliem. 
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1.4.2 Potential Roles in Liver Development and Regeneration 
miRNAs regulate about 30% of the protein-coding transcriptome (Filipowicz, 
Bhattacharyya et al. 2008) mainly through translational inhibition, or less commonly 
through translational activation (Vasudevan, Tong et al. 2007). miRNAs play an 
essential role in development, stress adaptation and hormone signaling (Leung and 
Sharp 2007). There is a growing interest for unraveling the potential roles for miRNAs 
during development. miRNAs have been shown to play key roles in cellular 
differentiation and fate determination (Yi, Poy et al. 2008). This can be due to 
targeting; transcription factors (Johnnidis, Harris et al. 2008), growth factor receptors 
(Eberhart, He et al. 2008), transcriptional repressors (Chen, Mandel et al. 2006) or 
proto-oncogenes (Xiao, Calado et al. 2007). 
Until now, up to 42 human liver-specific miRNAs and their target genes have been 
identified. Some examples are miR-122, miR-148a, miR-192 and miR-194. These 
liver-specific miRNAs showed higher levels of expression in the fetal than the adult 
liver samples (Liu, Fan et al. 2010). Their levels of expression in the fetal samples 
showed dynamic changes between different developmental stages, suggesting a 
possible role for miRNAs in fetal liver development (Liu, Fan et al. 2009; Tzur, Israel 
et al. 2009; Liu, Fan et al. 2010). Some of the miRNAs had multiple variants and were 
expressed in a synergetic manner during fetal liver development (Liu, Fan et al. 2009). 
miRNA expression levels were inversely correlated to the expression levels of the 
putative target genes (Tzur, Israel et al. 2009). 
Potential roles for miRNAs in liver development were further supported by Dicer 
deletion and miR-122 knockdown studies in mice. miR-122 is the most abundant 
among liver-specific miRNAs and miRNA depleted livers did not seem to be grossly 
affected up to 3 weeks postnatal. However, most of miRNA-deficient hepatocytes 
underwent early apoptosis and surviving animals had an increased incidence of 
hepatocellular carcinoma after 6 months (Esau, Davis et al. 2006; Elmen, Lindow et al. 
2008; Sekine, Ogawa et al. 2009).  
Both embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) showed a 
capacity to differentiate to hepatocytes. It is believed that miRNAs have important roles 
in stem cell differentiation. For example, miR-145 was suggested to downregulate the 
ESC pluripotency markers; octamer-binding transcription factor 4 (OCT4), SRY (sex 
determining region Y)-box 2 (SOX2) and Kruppel-like factor 4 (KLF4) (Xu, 
Papagiannakopoulos et al. 2009). Also, miR-302 was suggested to promote ESC 
mesodermal differentiation by inhibiting lymphoid enhancer-binding factor (LEF) 1 
and LEF2 expression (Rosa, Spagnoli et al. 2009).  
Full understanding for the different roles that miRNAs might play during ESC/iPSC 
differentiation to hepatocytes is still lacking. Upon ESC endodermal induction in vitro, 
targets for the two most upregulated miRNAs were shown to inhibit endodermal 
differentiation (Tzur, Levy et al. 2008). In a very interesting work published recently, 
miRNA expression profiles were studied during ESC differentiation to hepatocytes. In 
this study, miRNA expression patterns showed dynamic changes between ESCs, ESC-
derived endodermal cells and ESC-derived hepatocyte-like cells. In addition, miRNA 
profile for ESC-derived hepatocyte-like cells was similar to that for primary 
hepatocytes (Kim, Kim et al. 2011). 
After partial hepatectomy (PH), extensive miRNA profiling identified seven highly 
upregulated miRNAs, miR-21 was of particular interest. It was suggested that miR-21 
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facilitates efficient cell cycle progression by antagonizing Btg2, a gene restraining G1-
to-S transition phase (Song, Sharma et al. 2010). 
 
1.5 LIVER REGENERATION 
Due to its many essential functions, the liver is imparted a phenomenal capacity to 
regenerate. Liver regeneration was depicted in ancient Greek mythology by sinful 
Prometheus, whose liver was preyed by an eagle then renewed as fast as it was 
devoured providing him with eternal torture. Regeneration is a misnomer as resected 
tissue never grows back, but it is the remaining hepatocytes that compensate for the 
loss (Michalopoulos and DeFrances 1997). Hepatocytes have a tremendous replicative 
potential in vivo since only a few remaining hepatocytes can restore liver mass after 
profound injury (Overturf, Al-Dhalimy et al. 1999). Hepatocytes are normally long-
lived resting in G0 phase of the cell cycle and rarely undergo mitosis (Michalopoulos 
and DeFrances 1997). Upon injury, up to 95% of quiescent hepatocytes rapidly re-enter 
the cell cycle with an increase in DNA synthesis noticed about 12 hours later. Non-
parenchymal cells also re-enter cell cycle 2-3 days after hepatocytes (Stocker and Heine 
1971). DNA synthesis begins first in cells surrounding the portal vein streaming 
towards the central vein (Rabes, Wirsching et al. 1976), and liver mass restoration is 
achieved within 5-7 days (Grisham 1962). The regenerative response is proportional to 
the degree of loss in liver tissue with restoring minimal losses even less than 10%. 
Liver tissue mass in relation to body size is crucial with regeneration stopping after 
mass restoration. Interestingly, livers transplanted from larger- to smaller-sized animals 
underwent reduction in their mass to restore an optimum liver mass/body mass ratio 
(Francavilla, Ove et al. 1988). 
Strong evidence suggests the involvement of liver progenitor cells, e.g. SOX9 
expressing, in the restoration of liver mass rather than mature cells. SOX9 expressing 
liver progenitors from bile ducts differentiate to hepatocytes in a wave streaming from 
the portal vein towards the central vein restoring lost hepatocytes (Furuyama, 
Kawaguchi et al. 2011). Also, mesenchymal or stellate cells can give rise to hepatocyte-
like cells according to the mesenchymal-to-epithelial transition hypothesis (Choi and 
Diehl 2009). 
Liver regeneration implicates many genetic and metabolic events that need to be 
switched on and off properly. Liver regeneration passes through three different phases. 
The first phase is called ‘priming phase’ where transcription of early hepatocyte genes 
is induced. Transcribed genes, such as c-fos, c-jun and c-myc help promote transition of 
quiescent hepatocytes from G0 phase to G1 phase. The second phase is the metabolic 
and growth factor phase where an increase in metabolic demands on the remnant liver 
takes place. The third phase is the termination phase where stop signals suppress 
regeneration once liver mass restoration is achieved. Proteins from TGF-β family are 
suggested to have a role in termination of regeneration (Romero-Gallo, Sozmen et al. 
2005). 
Restoration of liver histology after regeneration is not well explained. Two-three days 
after PH, newly formed hepatocytes arrange themselves into small clumps around 
blood capillaries. Hepatic stellate cells then send their processes penetrating through 
hepatocyte clumps secreting laminins. Capillaries transform into true hepatic sinusoids 
restoring the typical relationship between hepatocytes, sinusoidal endothelial cells and 
Kupffer cells. The high laminin content of the extracellular matrix is changed to a 
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mature form with the introduction of other proteins such as fibronectin, collagen I and 
collagen IV (Martinez-Hernandez and Amenta 1995). By the end of the first week, 
typical hepatic histology is restored but with larger lobules and two cell-layered hepatic 
plates (Ogawa, Medline et al. 1979). 
However, liver regeneration is defective in many liver diseases. During cirrhosis there 
is a marked reduction in hepatocyte proliferative capacity with apparent failure in 
restoring normal liver histology. Defective hepatocyte proliferation could be due to 
expression of hepatocyte nuclear p21 and the progressive telomere shortening (Paradis, 
Youssef et al. 2001; Wiemann, Satyanarayana et al. 2002). There is strong evidence 
suggesting that regenerative nodules in cirrhotic liver originate from liver progenitor 
cells rather than from mature hepatocytes (Lin, Lim et al. 2010). Liver regeneration is 
also impaired in obesity and NASH (Farrell, Robertson et al. 2002). 
 
1.6 STEM CELL THERAPY FOR LIVER DISEASE 
Stem cells are defined as undifferentiated cells capable of; high proliferation, self-
maintenance, production of differentiated functional progeny and regenerating their 
tissues of origin (Potten and Loeffler 1990). The main functions of stem cells are to 
produce the whole organism during development, and to function as an internal repair 
system in mature tissues and organs. Thus, stem cells carry great promise in 
regenerative medicine to repair damaged tissues and organs. Based on their origin and 
their role in development or tissue repair, stem cells can be divided as ESCs and non-
embryonic (adult, somatic or tissue-specific stem cells such as MSCs). In 2006, a third 
stem cell type, iPSCs, was introduced when scientists succeeded to genetically 
reprogram mature cells to assume a stem cell-like state. 
We learned from liver regeneration that stem cells, mainly tissue-specific, may be 
involved in replacing damaged liver tissue. Theoretically, principles of hepatocyte 
transplantation can be also applicable with stem cell-derived hepatocyte-like cells, in 
terms of; cell numbers needed, site of application, mode of action, mechanisms of 
tissue integration and support of liver function for short or long periods. 
 
1.6.1 ESCs 
Human ESCs are usually derived from blastocyst stage embryos 5-6 day after in vitro 
fertilization. After their first discovery in 1998 (Thomson, Itskovitz-Eldor et al. 1998), 
a breakthrough in human ESC research has been initiated with the derivation of many 
cell lines and the improvement of cell culture conditions. Our laboratory actively 
participated in this field developing the standard non-fetal bovine serum (FBS)-
containing culture system using human, rather than mouse feeders (Hovatta, Mikkola et 
al. 2003; Inzunza, Gertow et al. 2005) and introducing a new mechanical animal-
reagent free, rather than enzymatic derivation technique (Strom, Inzunza et al. 2007). 
We have also developed a new feeder-free culturing system using human recombinant 
laminins (Rodin, Domogatskaya et al. 2010; Bergstrom, Strom et al. 2011). 
Given the optimum culturing conditions, human ESCs have unlimited multiplication 
and differentiation potentials, making them an ideal candidate for regenerative 
medicine. Differentiation to hepatocytes has been successfully reported using mouse, 
monkey and human ESCs (Lavon and Benvenisty 2005). For mouse ESC induction to 
hepatocytes a hepatic induction factor cocktail (Teratani, Yamamoto et al. 2005) or co-
culture with human non-parenchymal cells (Soto-Gutierrez, Navarro-Alvarez et al. 
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2007) have been used. For human ESC differentiation to hepatocytes, many 
differentiation protocols using activin A and HGF (Chen, Soto-Gutierrez et al. 2006), 
HGF and a synthetic fabric (Soto-Gutierrez, Navarro-Alvarez et al. 2006) have been 
used with varying degrees of success. Many other protocols trying to emulate the in 
vivo scenario of hepatocyte development have been published, first differentiating 
human ESCs to definitive endoderm then inducing hepatocyte differentiation followed 
by maturation induction (Basma, Soto-Gutierrez et al. 2009; Synnergren, Heins et al. 
2010; Sivertsson, Synnergren et al. 2012). 
 
1.6.2 iPSCs 
In 2006, iPSCs were introduced for the first time as a trial to bypass both ethical and 
immunological rejection concerns regarding human ESC use in regenerative medicine 
(Takahashi and Yamanaka 2006). Direct reprogramming of human fibroblasts to 
assume a pluripotent state has been done by viral transduction using the transcription 
factors Oct4, Sox2, and either cMyc and Klf4 (Takahashi and Yamanaka 2006), or 
Nanog and Lin28 (Yu, Vodyanik et al. 2007). Extensive research is being carried out 
for more efficient reprogramming of iPSCs using safer techniques (Okita, Matsumura 
et al. 2011). 
iPSCs have similar characteristics to those for ESCs in terms of; morphology, gene 
expression profiles, cell surface antigens and the high proliferative and differentiative 
capabilities (Ishikawa, Banas et al. 2012). Moreover, iPSCs are known to keep the 
same human leukocyte antigen (HLA) genotype of their parental somatic cells (Masaki, 
Ishikawa et al. 2007) giving the opportunity to treat patients using their own pluripotent 
stem cells. Similar to human ESCs, iPSCs showed their capability to differentiate to 
hepatocyte-like cells in vitro (Song, Cai et al. 2009; Si-Tayeb, Noto et al. 2010; Chen, 
Tseng et al. 2012), which then can be used in cell-based therapy for liver disease. 
Worthy of mentioning is that, iPSCs may also become immunogenic to their native 
host (Zhao, Zhang et al. 2011). 
 
1.6.3 MSCs 
MSCs were first identified in bone marrow (BM) as plastic-adherent fibroblast-like 
cells with colony-forming unit fibroblastic (CFU-F) properties (Friedenstein, 
Chailakhyan et al. 1974; Friedenstein, Latzinik et al. 1982; Friedenstein, Chailakhyan 
et al. 1987). An extensive research was then elicited, where many groups are trying to 
define, characterize, isolate and purify MSCs from different tissues. Yet, there is no 
clear cut definition for these cells with different nomenclature: mesenchymal stem 
cells, stromal stem cells, mesenchymal progenitors, among others. Relatively recently, 
the Mesenchymal and Tissue Stem Cell Committee of the International Society for 
Cellular Therapy suggested the name ‘multipotent mesenchymal stromal cells’ and put 
the minimal criteria for defining MSCs as: plastic adherence and CFU-F formation in 
standard culture conditions; with expression of CD73, CD90 and CD105; while lacking 
the expression of CD34, CD45, CD14 or CD11b, CD79α or CD19 and HLA-DR 
surface markers (Dominici, Le Blanc et al. 2006). The ‘stemness’ of MSCs is debated 
as they still lack unique multipotency markers, compared to pluripotent stem cells. 
Cultured MSCs may lose some of their markers and acquire other non-specific markers, 
but surprisingly, they can still keep their multipotency (Jones and McGonagle 2008). 
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The possibility for MSCs to differentiate to hepatocyte-like cells were first suggested in 
1999 (Petersen, Bowen et al. 1999), followed by another report few years later 
(Schwartz, Reyes et al. 2002). Many other reports came out supporting the same idea 
(Sato, Araki et al. 2005; Aurich, Sgodda et al. 2009), but with no strong evidence for 
MSC differentiation to hepatocyte-like cells having mature hepatocyte functions (Strom 
and Ellis 2011; Ishikawa, Banas et al. 2012). 
MSCs can be obtained from patients, expanded in vitro and transplanted back as an 
autologous cell therapy. Moreover, MSCs are immunoprivileged with absent 
expression of HLA-II, making them ideal also for allogeneic cell therapy (Le Blanc, 
Tammik et al. 2003; Le Blanc, Frassoni et al. 2008). There is strong evidence for MSCs 
acting as ‘trophic mediators’ where they secrete bioactive reagents, which function as 
either immumosuppressors or promoters of regeneration (Caplan and Dennis 2006). 
Allogeneic MSC transplantation has been suggested to support hepatocyte survival, 
proliferation and function both in vivo and in vitro and to decrease the host allogeneic 
response to transplanted hepatocytes and modulate stellate cell activation in liver 
cirrhosis causing its regression (Isoda, Kojima et al. 2004; Gomez-Aristizabal, Keating 
et al. 2009). A promising phase-1 clinical trial strongly supported MSC clinical use in 
liver cirrhosis (Mohamadnejad, Alimoghaddam et al. 2007). 
Fetal MSCs were suggested to have stronger therapeutic potentials being more 
primitive and having marked proliferative (Gotherstrom, West et al. 2005; Guillot, 
Gotherstrom et al. 2007) and differentiative (Chan, Waddington et al. 2007; Kennea, 
Waddington et al. 2009) capacities compared to their adult equivalents. Fetal MSCs 
were also able to inhibit lymphocyte proliferation induced by mitogens (Gotherstrom, 
Ringden et al. 2003). 
 
1.7 CRYOPRESERVATION AND COLD STORAGE 
1.7.1 Hepatocyte Cryopreservation 
Hepatocyte cryopreservation is essential for the availability of hepatocytes and stem 
cell-derived hepatocyte-like cells for emergency as well as planned treatment for liver 
disease patients and also for providing hepatocytes for drug toxicity and metabolism 
studies. The first successful trials for hepatocyte cryopreservation were performed in rat 
in 1980 (Fuller, Morris et al. 1980) and in human in 1986 (Loretz, Li et al. 1989). Since 
then, many groups have made efforts in developing better cryopreservation protocols 
(Rijntjes, Moshage et al. 1986; Dou, de Sousa et al. 1992; Li, Lu et al. 1999; 
Alexandre, Viollon-Abadie et al. 2002; Hewitt 2010; Terry, Dhawan et al. 2010). In 
spite of such efforts, significant loss of viability and function after thawing is still a 
major problem calling for further optimization for available hepatocyte 
cryopreservation protocols. 
The key factors in hepatocyte cryopreservation are: FBS, DMSO and the university of 
Wisconsin solution (UW). FBS supports hepatocytes during cryopreservation by: 
containing several growth and attachment factors, metal transporters, protease 
inhibitors, among others; providing mechanical protection for cells; and having a 
buffering capacity. However, it is not suitable for clinical purposes because of its 
animal origin. UW, on the other hand, is a xeno-free solution that helps support 
hepatocytes during cryopreservation by: minimizing injury from hypothermia and 
oxygen free radicals, preventing intracellular acidosis and interstitial tissue expansion 
as well as providing a source of energy for hepatocytes. DMSO, the standard 
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cryoprotectant allows for only a moderate increase in solute concentration during 
freezing and preserves membrane integrity by interacting with membrane 
phospholipids (Hewitt 2010). 
 
1.7.2 Hepatocyte Cold Storage 
During hepatocyte transplantation, it has been shown that only what equals to 5% of the 
total liver mass can be infused at a time. Hepatocyte infusion has to be performed 
slowly over several hours to days to avoid the risk for portal vein thrombosis (Fox, 
Chowdhury et al. 1998). This necessitates the need for an efficient cold preservation 
method for hepatocytes. 
Cold storage of hepatocytes aims at storing them for shorter periods without 
cryopreservation. A hepatocyte preservation solution is needed and many solutions 
such as UW, Histidine-tryptophan-ketoglutarate (HTK) and Celsior have been tested 
(Abrahamse, van Runnard Heimel et al. 2003). Several studies have succeeded in cold 
storage of isolated hepatocytes for more than 3 days, albeit with marked loss of 
viability and function (Gramignoli, Marongiu et al. 2011; Pless, Sauer et al. 2012). 
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2 AIMS 
The main aim for this thesis was to study various aspects of cellular therapy for liver 
disease as an alternative to liver transplantation. To fulfill this aim, 4 studies were 
carried out with the following specific aims: 
 
1. To identify and characterize a mesenchymal stem cell population within the 
human fetal liver, and evaluate the cells’ differentiation potential to 
hepatocytes.  
 
2. To profile and identify microRNAs important for the development in human 
fetal and adult liver. 
 
3. To optimize a xeno-free cryopreservation protocol for primary human 
hepatocytes.  
 
4. To optimize a cold storage protocol for primary human hepatocytes. 
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3 MATERIAL AND METHODS 
 
3.1 ETHICS STATEMENT 
Human fetal liver samples were used for MSC isolation and immunohistochemistry 
(paper I & preliminary data) and for miRNA isolation (paper II). The samples were 
obtained from fetuses aborted during the first trimester by modified vacuum curettage 
from volunteered women who donated the fetal tissues. An informed written consent 
was obtained from each donor. 
Human adult liver samples were used for obtaining primary hepatocytes (papers II, III, 
& IV). The samples were also used for immunohistochemistry (paper I) and TUNEL 
staining (paper IV). Used samples were obtained from liver resections or from deceased 
organ donors. An informed written consent was obtained for each sample. 
Peripheral blood samples were taken from healthy volunteers who have donated the 
blood (paper I). An informed written consent was obtained from each donor. 
C57 black/nude mice (preliminary data) were housed at the animal facility, Karolinska 
University Hospital, Huddinge, Sweden. The animals were housed according to the 
Animal Care and Use Facility at the Karolinska University Hospital. 
All studies were approved by the Regional Ethical Review Board in Stockholm, 
Sweden and the IRB protocol, University of Pittsburgh, PA, USA. The studies were 
done in compliance with the international guidelines regarding the use of human tissue 
in research. 
 
3.2 CELL ISOLATION 
3.2.1 MSCs from Human Fetal Liver 
To isolate MSCs from human fetal liver (hFL-MSCs), single cell suspension was first 
prepared (paper I). Fetal liver samples were gently disintegrated by pressing them 
against a 70µm cell strainer. CD271, an MSC marker, was used to positively isolate a 
pure population of MSCs by adding magnetic beads labeled with CD271 to the cell 
suspension. After isolation, hFL-MSCs in the positive fraction were cultured in MSC 
medium, composed of Dulbecco’s Modified Eagle’s Medium Low Glucose (DMEM-
LG), supplemented with 10% FBS, 1% Glutamax and 1% penicillin-streptomycin. 
 
3.2.2 Primary Human Hepatocytes 
Hepatocytes were isolated using a three-step collagenase perfusion procedure (papers 
II, III & IV). First, liver samples were perfused with warm (37°C) Hank’s buffered salt 
solution (HBSS) containing ethylene glycol tetraacetic acid (EGTA) to flush blood out 
of the sample. As a calcium chelating agent, EGTA helps disrupt cell adhesion to 
extracellular matrix. Second, perfusion with warm HBSS alone was done to wash out 
remaining EGTA, as digestive enzymes are dependent on calcium and magnesium for 
their activation. Finally, liver tissue was perfused with warm Eagle’s Minimum 
Essential Medium with Earle’s salts containing collagenase XI for enzymatic 
dissolution. Undigested tissue pieces were removed by filtration through sterile gauze 
while hepatocytes were collected by low speed centrifugation. Hepatocyte medium was 
composed of Williams E medium without phenol red supplemented with 5% FBS, 
insulin (10-7M), dexamethasone (10-7M) and an antibiotic-antimycotic. 
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3.3 ASSESSMENT OF CELLULAR VIABILITY 
The trypan blue exclusion method (TB) was used for assessment of cell viability 
indirectly by evaluating cell membrane integrity (papers I, III, & IV). Dead cells with 
disrupted cell membrane allow the passage of trypan blue through the membrane, 
which in turn stains the cytoplasm blue. 
In (paper III), in addition to TB, viability of the hepatocytes was further evaluated by 
the Live/Dead Assay (LDA). LDA is a two-colour viability assay where two 
fluorescent probes are used for assessing cell membrane integrity and intracellular 
esterase activity; ethidium homodimer-1 (EthD-1) and calcein acetoxymethyl (calcein 
AM), respectively. Live cells actively take up the non-fluorescent cell-permeable 
calcein AM where intracellular esterase cleaves it producing the intensely fluorescent 
calcein. EthD-1 crosses damaged cell membrane and binds nucleic acids. 
 
3.3.1 Apoptosis Assays 
The previous methods for viability assessment mainly detect metabolically non-viable 
necrotic cells, which have lost their membrane integrity. Apoptosis assays aim at 
detecting the early events in programmed cell death (paper IV). Apoptotic cells are 
metabolically viable cells having; a blebbing, albeit intact, cell membrane, uniformly 
condensed chromatin, uniformly fragmented DNA and with specific enzyme cascades 
initiated (Thompson, Strange et al. 1992). 
 
3.3.1.1 TUNEL Test 
The TUNEL test is designed for the detection of uniform nucleosome-sized DNA 
fragments by labeling their 3’OH termini in situ with modified nucleotides. The 
nucleotides are fixed to the DNA by the enzyme terminal deoxynucleotidyl transferase 
(TdT). TdT labels both single-stranded and double-stranded DNA fragments (Gavrieli, 
Sherman et al. 1992). Anti-digoxigenin antibody labeled with a peroxidase reporter 
molecule binds digoxigenin-conjugated nucleotides. DAB, a peroxidase chromogenic 
substrate, is added to the treated liver tissue and cytospinned hepatocyte slides for color 
development. Positive cells were counted under light microscopy. 
 
3.3.1.2 Caspase 3/7 Assay 
Caspases are a family of proteases playing key roles in apoptosis in mammalian cells. 
Caspases 3 and 7 are important members in this family (Bayascas, Yuste et al. 2002). 
Upon treating lysed hepatocytes with a luciferin-derived caspase substrate, caspases 
cleave it freeing luciferin and generating a luminescent signal to be detected by a 
luminometer. The luminescence generated is proportional to caspase activity reflecting 
the degree of apoptosis within hepatocytes. 
 
3.4 CHARACTERIZATION OF HUMAN FL-MSCS  
3.4.1 Marker Expression 
hFL-MSCs were characterized on both the protein and functional levels. The 
expression of known mesenchymal and lack of expression of non-mesenchymal 
markers were demonstrated by flow cytometry analysis and immunocytochemical 
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staining (ICC) (paper I). The markers tested by flow cytometry included CD271, CD31, 
CD73, CD90, CD80, CD86, CD105, CD44, CD14, CD34, CD45, HLA-DR, HLA class 
I and HLA class II. Mesenchymal marker expression was further confirmed by ICC for 
CD271, CD90, CD34, CD45, CD73, CD105 and CD166. 
Being derived from human fetal liver, hFL-MSCs were also examined for their 
expression of certain hepatic markers. ICC staining was done for α-fetoprotein (AFP), 
albumin (ALB), CK18 and CK19 (paper I). 
 
3.4.2 Differentiation Potential 
A mesenchymal origin for hFL-MSCs was further confirmed by evaluating their 
differentiation potential towards adipogenic and osteogenic lineages in vitro (paper I). 
The potentiality for hFL-MSCs to differentiate towards hepatogenic lineages was also 
tested in vitro (paper I). 
 
3.4.2.1 Osteogenic Differentiation 
For osteogenic stimulation (paper I), hFL-MSCs were treated with DMEM-LG 
supplemented with dexamethasone, glycerophosphate, ascorbic acid-2-phosphate, FBS 
and penicillin-streptomycin. Von Kossa staining, based on the use of silver nitrate, 
detects calcium phosphate deposited in the extracellular matrix by differentiating hFL-
MSCs. Calcium is reduced by light exposure and gets replaced by silver ions forming 
silver phosphate, which is then degraded by light forming silver. Alizarin red S directly 
binds calcium in the extracellular matrix by labelling its deposits in differentiating hFL-
MSCs. 
 
3.4.2.2 Adipogenic Differentiation 
For adipogenic stimulation (paper I), hFL-MSCs were alternatively treated with an 
induction medium composed of: DMEM-high glucose (DMEM-HG), 1-methyl-3-
isobutylxanthine, insulin, indomethacin, dexamethasone, FBS as well as penicillin-
streptomycin and a supportive medium composed of: DMEM-HG, insulin, FBS and 
penicillin-streptomycin. Fat droplets within differentiating hFL-MSCs were detected by 
Oil Red O staining, where Oil Red directly labels lipids. 
 
3.4.2.3 Hepatogenic Differentiation in vitro 
Whether hFL-MSCs were able differentiate to hepatocytes in vitro (paper I) was 
determined by treating them with an induction medium containing: Iscove’s modified 
Dulbecco’s medium (IMDM) with HGF, basic FGF, nicotinamide and insulin-
transferrin-selenium (ITS) and thereafter a maturation medium containing: IMDM with 
oncostatin M, dexamethasone and ITS. hFL-MSCs were stained for hepatic marker 
expression and tested for CYPs activity (see below). 
 
3.4.2.4 Hepatogenic Differentiation in vivo (Preliminary) 
hFL-MSC potentiality to differentiate to hepatocytes in vivo was preliminary tested by 
their transplantation to C57 black/nude mice. hFL-MSCs isolated using a cell depletion 
cocktail including monoclonal antibodies to the following lineage specific cell surface 
antigens (Glycophorin A, CD3, CD14, CD19, CD66b and CD38) were used. hFL-
MSCs were transduced with green fluorescent protein (GFP). GFP transduction was 
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done using a recombinant lentiviral vector produced using a 3-plasmid expression 
system as described elsewhere (He, Ehrnfelt et al. 2004). One million cells were 
injected in a volume of 300µl DMEM-LG intra-splenic after partial hepatectomy to 
give a space advantage for the transplanted cells. Mice were injected with retrorsine, 
70mg/kg, intra-peritoneal a week before transplantation. Retrorsine inhibits host 
hepatocyte proliferation giving, in addition, a growth advantage for the transplanted 
hFL-MSCs. In addition to five hFL-MSC-transplanted animals, two animals were 
sham-operated and two more were kept as control. Fresh frozen cryosections of mouse 
liver were examined for GFP expression and ICC-stained for the following human 
hepatic markers; ALB, AFP, CK18 and CK19. 
 
3.4.3 Immunomodulatory Effects 
To test for immunogenicity and immunomodulatory properties of hFL-MSCs (paper I), 
mixed lymphocyte cultures (MLCs) were performed with adult peripheral blood 
lymphocytes (PBLs). Triplicate samples of PBLs were cultured with irradiated 
autologous or allogeneic PBLs pooled from five donors with or without irradiated hFL-
MSCs. The immunogenicity and immunomodulatory properties of hFL-MSCs were 
similarly tested in MLCs including hFL-MSCs, PBLs and HepG2 cells, a human 
hepatocellular carcinoma cell line. The immunomodulatory aspects of hFL-MSCs are 
of interest for their potential transplantation to patients with liver disease, either alone 
or together with other cell types, such as hepatocytes. 
 
3.5 MICRORNA PROFILING 
Stem cell differentiation to hepatocytes is extensively studied, and huge effort is being 
employed for optimization of differentiation protocols. Our attempts to differentiate 
hFL-MSCs to hepatocytes both in vitro and in vivo are mentioned in this thesis. A 
potential role for miRNAs in liver development has been widely suggested and a 
miRNA-based stem cell differentiation protocol is a future aim. Extensive microarray 
profiling for miRNA expression in human fetal and adult liver has been initiated here 
(paper II). The aim was to identify the key miRNA players in liver development. 
 
3.5.1 Microarray Analysis 
Total RNA was extracted from fetal and adult liver samples using a miRNA-specific 
extraction kit to preserve small RNA fraction during extraction. Total RNA 
concentration, quality and integrity were analyzed prior to microarray hybridization. 
Microarray analysis was performed to compare the expression of individual miRNAs in 
the different liver samples. Microarray data were processed with the R software 
package where linear models followed by moderated t-test analyses were used to 
identify differentially expressed miRNAs between adult and fetal liver samples. 
 
3.5.2 miRNA Target Prediction 
Target prediction aimed at identifying potential gene targets for enriched miRNAs. 
miRNAs with at least two-fold higher expression were selected for target prediction 
bioinformatically using the miRWalk Database. Similarity scores were calculated for 
the predicted targets upon comparing them to previously published lists of specific 
tissue selective genes. Genes intersected between predicted and listed fetal liver genes 
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were identified as candidate gene set for fetal liver miRNAs. Another candidate gene 
set for adult liver miRNAs was similarly prepared. 
 
3.5.3 Pathway Analysis 
Pathway analysis aimed at the bioinformatic linking of specific miRNA target genes to 
specific physiological/pathological processes. Both candidate gene lists prepared before 
for fetal and adult liver miRNAs were tested. Results from target pathway analysis 
were further discussed against previously published data. 
 
3.5.4 Quantitative RT-PCR Analysis (qRT-PCR) 
qRT-PCR analysis aimed at confirming the microarray data. The three highly expressed 
miRNAs in the fetal liver samples and the two highly expressed miRNAs in the adult 
liver samples were selected for further qRT-PCR confirmation in three new fetal and 
three new adult liver samples. miRNA relative expression in the adult and fetal samples 
was calculated and t-test values were estimated. 
 
3.6 CHARACTERIZATION OF HEPATOCYTES  
3.6.1 CYPs Activity 
Primary human hepatocytes and hFL-MSCs differentiated to hepatocytes were tested 
for their CYPs activity (papers I, III, & IV). Activity of the major CYPs; CYP1A2, 
CYP2C9, CYP2C19, CYP2D6, CYP3A4 and CYP3A7 was assessed. Luminescence-
based assays utilizing luciferin-derived P450-Glo substrates and their specific luciferin 
detection reagents were used. CYPs inside the cells metabolize substrates and free 
luciferin, which is then metabolized by luciferase in the detection reagent. Activity of 
the CYPs was estimated as the degree of luminescence emitted from hepatocytes. 
CYPs were sometimes induced by β-naphthoflavone (BNF) (CYP1A1/2), rifampicin 
(RIF) phenobarbital (PB) (CYP 3A4) or DMSO (vehicle control) (paper IV). 
 
3.6.2 7-Ethoxyresorufin Metabolism 
Activity of CYP1A1/2 was also tested by the ability of the cells to convert 7-
ethoxyresorufin to resorufin (paper IV). The conversion is effected by the 7-
ethoxyresorufin-O-deethylase (EROD) enzyme (Burke and Mayer 1974). Cells were 
incubated with 7-ethoxyresorufin, and the fluorescence of the outproduct resorufin 
reflected CYP1A1/2 activity. Salicylamide was added to block the phase II enzymes 
metabolizing resorufin itself. A resorufin sodium standard curve was run in parallel to 
quantify the amount of resorufin formed.  
 
3.6.3 Resorufin Metabolism 
While CYPs activity reflects phase I liver activity, resorufin metabolism reflects phase 
II function. Resorufin undergoes glucuronidation and sulfation by phase II enzymes 
forming non-fluorescent compounds (Gonzalez, Reimschuessel et al. 2009). Cells were 
incubated with resorufin and the decrease in its fluorescence was measured (paper IV). 
Similarly, a resorufin sodium standard curve was run in parallel to quantify the amount 
of resorufin loss. 
 
 26 
3.6.4 Ammonia Detoxification 
Ammonia detoxification is a major hepatic function, and hepatic encephalopathy due to 
ammonia accumulation is a serious problem accompanying liver cell failure. Five 
enzymatic reactions are involved in the urea cycle of converting ammonia into urea, 
which is then eliminated through the kidneys. 
Cells were incubated with ammonium chloride and three reagents were used for 
colorimetric estimation of ammonia clearance (paper IV). Reagent A contained sodium 
tungstate, as well as sulphuric and phosphoric acids; reagent B contained phenol and 
sodium nitroprusside; while reagent C had potassium carbonate and sodium 
hypochlorite. Ammonia reacts with hypochlorite forming monochloramine that reacts 
with phenol forming an indophenol derivative with a deep blue color (Brautigam, 
Gagneul et al. 2007). An ammonium chloride standard curve was run in parallel to 
quantify ammonia metabolism. 
 
3.6.5 Plating Efficiency 
Plating efficiency is the ability of hepatocytes to attach to the culture dish and is 
considered as an indicator of hepatocyte ability to engraft into the host liver after 
transplantation (Wan, Zhang et al. 2012). Plating efficiency was calculated as the 
protein content of attaching hepatocytes divided by that of both attaching and non-
attaching hepatocytes (paper IV). A protein harvesting solution containing; Tris, 
potassium chloride, EDTA and protease inhibitor was used for collecting protein. A 
colorimetric protein assay based on the Coomassie blue dye was used for protein 
estimation. Coomassie blue binds to primarily basic and aromatic amino acid residues, 
especially arginine (Compton and Jones 1985). A protein standard curve, e.g. using 
bovine serum albumin (BSA), was run in parallel for quantification. 
 
3.6.6 Normalization of Enzyme Activity 
Results of the functional assays were related to the actual number of the cells tested. 
This was done by normalizing the results to one million viable cells, or to the amount 
of protein or DNA within the cells tested. Protein content was estimated as described 
before for plating efficiency calculation. A Hoechst 33258-based fluorescent assay 
selective for double stranded DNA (dsDNA) was used. A dsDNA standard curve was 
run in parallel for quantification. 
 
3.7 COLD PRESERVATION 
Saving cells for longer periods, through cryopreservation, or for shorter periods, 
through cold storage, is an essential component of clinical cell transplantation in liver 
disease. This applies to primary human hepatocytes, stem cell-derived hepatocyte-like 
cells and any other candidate cell type. Primary human hepatocytes, the first candidate 
for transplantation, were used for optimizing both cryopreservation and cold storage 
protocols. 
 
3.7.1 Cryopreservation of Hepatocytes  
It has been suggested that controlled rate freezing (CRF) in special freezers is superior 
to ordinary polystyrene box freezing (PSB). A comparison between both methods was 
carried out (paper III). 
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3.7.1.1 Controlled Rate Freezing 
Hepatocytes in (UW + 12% DMSO) were transferred to cryotubes on ice. Half of the 
tubes were frozen in a controlled rate freezer and transferred to the vapor phase of a 
liquid nitrogen tank. The other half of the tubes were wrapped in tissue paper and put 
into a common laboratory PSB. The box was sealed, shut with a tape and quickly 
placed into a -70°C freezer. After two days, the frozen tubes were transferred to the 
vapor phase of a liquid nitrogen tank for storage. 
 
3.7.1.2 Polystyrene Box Freezing 
Two different cryopreservation solutions have been tested, the standard (UW + 12% 
DMSO) and a new xeno-free medium, containing 10% DMSO (permeating) and a high 
polymer anhydrous dextrose (non-permeating) cryoprotectants. The cryotubes were 
placed in PSB and kept at -70°C for overnight and then moved to the vapor phase of a 
liquid nitrogen tank for storage. When thawed, cryotubes were first incubated in a 
water bath at 37°C for 1-2 minutes, and then cells were resuspended in cold hepatocyte 
medium. For cells frozen in the new solution, a specific thawing buffer was used before 
the cells being resuspended in the hepatocyte medium. 
Viability of the hepatocytes using trypan blue and LDA was compared between fresh 
hepatocytes, the two box freezing protocols and the CRF method. CYPs activity was 
also compared among the different groups. 
 
3.7.2 Cold Storage of Hepatocytes  
For cold storage, preservation of whole liver tissue was compared to preservation of 
single hepatocytes (paper IV). UW was used in both protocols. Liver tissue was divided 
into two pieces and hepatocytes were isolated as mentioned above. Hepatocytes were 
analyzed directly after isolation (fresh) or after storage for 48 hours at 4°C in UW, 
referred to as (UW cells). Liver tissue from the same donor was stored at 4°C in UW 
and hepatocytes were isolated after 48 hours, referred to as (UW tissue cells). Viability 
of the hepatocytes was evaluated in both groups as mentioned above. Hepatocyte 
plating efficiency, ammonia metabolism, activity of CYP1A1/2, -2C9, -3A7 and -3A4, 
phase II conjugation as well as apoptosis evaluation by TUNEL assay and caspase 3/7 
activities were also compared between groups as described above. 
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4 RESULTS 
 
4.1 MSCS IDENTIFIED IN HUMAN FETAL LIVER 
Data in (paper I) suggested the presence of an MSC population in human fetal liver, 
which we named hFL-MSCs. hFL-MSCs that were positively isolated using CD271-
labelled magnetic beads were a homogenous population. 
 
4.1.1 CD271 positive Cells in Human Liver 
Cultured fetal liver cells as well as fetal and adult liver sections showed positive 
staining for the mesenchymal marker CD271 (figure 4.1). CD271 expression was 
higher in the fetal liver (70.1%) than in the adult (23.4%). 
 
4.1.2 Mesenchymal Phenotype 
 hFL-MSCs had a mesenchymal immunophenotype upon ICC staining and flow 
cytometry analysis. By flow cytometry, cultured hFL-MSCs were positive for; CD105 
(SH2), CD44, CD73 (SH4), CD90 (Thy1) and HLA class I (more than 90%) and 
negative for; CD14, CD45, CD31, CD34, CD80, CD86, HLA class II and HLA-DR 
(less than 5%). hFL-MSCs were partially positive for CD271 (17-20%). 
 
4.1.3 Mesodermal Differentiation 
hFL-MSCs showed the ability to differentiate towards osteogenic and adipogenic 
lineages in vitro as shown by Von Kossa/Alizarin Red staining and Oil Red O staining, 
respectively (figure 4.2). Staining quantification showed that different samples had 
different differentiation potentiality. 
 
4.1.4 Hepatogenic Differentiation 
Despite their liver origin and their prior expression of hepatic markers, hFL-MSCs did 
not differentiate, in our hands, towards hepatic lineages when stimulated in vitro. 
Differentiating cells did not show any CYPs activity and even started to lose their 
hepatic marker expression as noticed from ICC staining. 
 
4.1.5 Immunomodulatory Properties  
MLCs suggested that hFL-MSCs were non-immunogenic when 10% hFL-MSCs were 
co-cultured with peripheral blood lymphocytes (PBLs) in vitro, as they did not elicit an 
immune response (n=6) (figure 4.3). 
When cultured with PBLs and HepG2 cells, hFL-MSCs continued to be non-
immunogenic and even modulated the PBL immune response to the HepG2 cells. 
When 10% hFL-MSCs was added to co-cultures of PBLs and HepG2 cells, hFL-MSCs 
had variable effects on allogeneic PBLs responses towards HepG2 cells: one hFL-MSC 
sample markedly inhibited lymphocyte proliferation by 63.3% (STDEV 37.2%) the 
second sample did not have any marked effect on lymphocyte proliferation and the 
third sample even stimulated lymphocyte proliferation by 22% (STDEV 24.8%) 
compared to MLC with HepG2 (n=6) (figure 4.3). 
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Figure 4.1: Enzymatic peroxidase immunochemical staining for CD271 expression in frozen sections from 
human fetal and adult liver as well as fetal liver cells (FLCs). Isotype controls were included. DAB (in fetal 
and adult liver sections) and AEC (in FLCs) substrates were used for color development. Brown color 
indicates positive staining. Some hepatoblasts (H) stained positive for CD271. In the adult liver, CD271 was 
mainly expressed in the portal area (P). Magnification 20X. 
Figure 4.2: Osteogenic and adipogenic differentiation of CD271-isolated mesenchymal stem cells from 
human fetal liver (hFL-MSCs). hFL-MSCs from passages 3-5 were stimulated with osteogenic (3 weeks) or 
adipogenic (3 cycles) media. An aliquot of cells were grown in MSC medium as a control. Control (A, B) and 
osteogenic stimulated hFL-MSCs were stained with Von Kossa (D, black staining) and Alizarin red S (E, red 
staining) for calcium deposition. Control (C) and adipogenic stimulated (F) hFL-MSCs were stained with Oil 
red O to visualize lipid droplets (red staining). Typical pictures are shown for the differentiation. 
Magnification 20X. Alizarin red S staining of 3 osteogenic stimulated hFL-MSC samples (hFL-MSC1-3) was 
eluted by addition of 10% (w/v) cetylpyridinium chloride (G). Oil red O staining of 3 adipogenic stimulated 
hFL-MSC samples (hFL-MSC1-3) was eluted by addition of 100% isopropanol (H). Absorbance was 
measured at 500 nm (Oil red O) or at 562 nm (Alizarin red S) and plotted as differentiated hFL-MSCs times 
control hFL-MSCs. All samples were performed in duplicates. 
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4.1.6 hFL-MSC Transplantation to Mice (Preliminary Data) 
MSCs previously isolated from human fetal liver and transduced with GFP were 
transplanted into mice after partial hepatectomy. The preliminary results suggested 
successful homing, engraftment, and survival of transplanted hFL-MSCs for at least 
two weeks after transplantation. Fresh frozen cryosections from transplanted mice 
livers clearly showed the green fluorescence of GFP-transduced cells. In addition, ICC 
staining of mouse liver sections for human specific ALB, AFP, CK18 and CK19 
suggested the presence of human hepatocyte-like cells within the liver in the hFL-
MSC-transplanted group (figure 4.4). 
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Figure 4.3: Mixed lymphocyte cultures (MLCs) with mesenchymal stem cells from human fetal liver (hFL-
MSCs). 10% irradiated third party hFL-MSCs were co-cultured for six days with 200,000 responder and/or 
stimulator cells. Counts-per-minute depicts thymidine incorporation in the responder cell DNA. Mean ± STD 
of 6 experiments. (A) Lymphocyte immunological reaction towards hFL-MSCs at 6 days. (B) hFL-MSCs 
were co-cultured for six days with responder peripheral blood lymphocytes (PBLs) and an irradiated pool of 
stimulator PBLs, respectively. (C) hFL-MSCs were co-cultured for six days with responder PBLs and 
irradiated stimulator HepG2 cells, respectively. 
Figure 4.4: Liver sections from mice transplanted with hFL-MSCs: Fresh frozen section showing GFP-
transduced hFLMSCs (A). Paraffin section stained with a FITC-conjugated anti-human albumin antibody (B). 
Peroxidase staining for anti-human antibodies for α-fetoprotein (C), CK19 (D), CK18 (E) and their isotype 
control (F) and substrates used for colour development were DAB (C,D) and DAB-Ni (E).  
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4.2 MICRORNAS PROFILED IN HUMAN LIVER 
Extensive profiling for miRNA expression in human fetal and adult livers was done by 
microarray analysis (paper II). Bioinformatic target prediction and pathway analysis 
suggested the involvement of enriched miRNAs in fetal liver development and 
erythropoiesis. 
 
4.2.1 Microarray Analysis 
Microarray data identified 154 miRNAs to be significantly expressed in both fetal and 
adult liver samples. Of these, 74 miRNAs were expressed on a higher level in the fetal 
compared to the adult liver, with 48 miRNAs having at least two-fold higher 
expression. Similarly, 80 miRNAs were expressed on a higher level in the adult 
compared to the fetal liver, with 37 miRNAs having at least two-fold higher expression. 
Many of the listed miRNAs have been previously linked to fetal liver development. In 
addition, many of the highly expressed fetal miRNAs were previously linked to 
erythropoiesis. 
 
4.2.2 Target Prediction 
miRWalk database analysis linked 24 out of the 48 fetal miRNAs and 7 out of the 37 
adult miRNAs to 12588 and 8474 gene targets respectively. Identified targets were 
compared to previously published target lists of tissue specific miRNAs (figure 4.5). 
Similarity testing between predicted and previously published targets identified a 
candidate gene set of 60 targets for fetal miRNAs (fetalGS) and of 26 targets for adult 
miRNAs (adultGS) to be cross-listed. 
 
4.2.3 Pathway Analysis 
Further pathway analysis for both gene sets linked selected miRNAs to certain 
physiological processes, such as extracellular matrix-receptor integration, complement 
and coagulation cascade, steroid hormone biosynthesis, glycolysis and gluconeogenesis 
(figure 4.6a&b). Many of these processes are known to be related to liver development 
and/or function. 
 
4.2.4 Quantitative RT-PCR Confirmation 
The qRT-PCR results confirmed the microarray data for selected miRNAs. 
Differentially expressed fetal and adult miRNAs continued to have similar expression 
pattern in the qRT-PCR. 
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Figure 4.5: Com
parison betw
een targets for selected m
iRN
A
s and tissue-selective gene sets published by G
reco et al., 2008 (G
reco, Som
ervuo et al. 2008). Sim
ilarity values 
betw
een fetal enriched and published targets are presented w
ith blue circles and those for adult targets are show
n in red. Sim
ilarity betw
een predicted and published lists w
as higher 
in case of fetal and adult liver tissues. 
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Figure 4.6a: Pathw
ay analysis for the target set for selected fetal liver m
iRN
A
s. The dentogram
 show
s m
iRN
A
s and the pathw
ays linked to them
. D
arker color 
indicates stronger correlation. Selected fetal liver m
iRN
A
s w
ere obviously linked to extracellular m
atrix-receptor integration, glucose m
etabolism
, coagulation cascades 
and steroid horm
one biosynthesis. 
   35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6b: Pathw
ay analysis for the target set for selected adult liver m
iRN
A
s. The dentogram
 show
s m
iRN
A
s and the pathw
ays linked to them
. D
arker color indicates 
stronger correlation. Selected adult liver m
iRN
A
s w
ere obviously linked to m
etabolic functions such as m
etabolism
 of fructose, m
annose and arachidonic acid. 
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4.3 NEW XENO-FREE HEPATOCYTE FREEZING PROTOCOL 
Two important comparisons, CRF to ordinary box freezing and two box freezing 
protocols were done in (Paper III). 
 
4.3.1 Controlled-rate Freezing 
In our hands, CRF did not appear to be superior to, but even worse than ordinary PSB 
freezing as noticed from hepatocyte viability (table 4.1). 
 
 
 
 
 
 
 
 
 
 
 
 
4.3.2 New PSB Freezing Protocol 
In paper III, we introduced a new xeno-free hepatocyte cryopreservation protocol, 
referred to as (CB). The CB protocol seemed to be superior to the standard protocol, 
referred to as (DMSO-UW). Cell viability was compared between freshly isolated and 
cryopreserved hepatocytes using TB and LDA. Viability using CB was significantly 
higher than that using DMSO-UW (figure 4.7). 
 
4.3.3 CYPs Activity 
Although there was a tendency for CYPs activity to be a bit higher in the CB compared 
to DMSO-UW group, high within-groups variability seemed to preclude any between-
group differences. This was manifested by the high standard deviation values that 
exceeded mean values in many cases (figure 4.8). 
 
 
 
 
 
 
 
 
 
 Viability Fresh%  PSB% CRF% 
L1 75 22 6 
L2 74 38 22 
L3 83 42 18 
L4 73 40 37 
Table 4.1: Comparison between controlled 
rate freezing (CRF) and polystyrene box 
freezing (PSB). PSB gave a viability of (35.5 ± 
9.2), not significantly different from the freshly 
isolated (76.3 ± 4.6). CRF gave a significantly 
lower viability (2.8 ± 12.8) (p<0.01) compared 
to fresh. Figures represent percent ± SD of 
viable cells using trypan blue. 
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Figure 4.7: Hepatocyte viability before and after freezing: Viability in the three groups; fresh 
hepatocytes (FRESH) and hepatocytes frozen using either the new protocol (CB) or the standard 
DMSO-UW protocol (DMSO) using both the trypan blue exclusion and the Live/Dead Assay (LDA) 
methods. There was a significant difference in viability between CB and DMSO using the two-way 
ANOVA test (P < 0.05). Figures represent percent ± SD of viable cells using TB. 
Figure 4.8: Hepatocyte functionality before and after freezing: Activity of the major cytochrome P450 
enzymes; CYP1A2, CYP2C9, CYP3A7, CYP3A4, CYP2C19 and CYP2D6 for the fresh hepatocytes 
(FRESH) compared to hepatocytes cryopreserved using either the new protocol (CB) or the standard 
DMSO-UW protocol (DMSO). The standard deviation exceeded the mean in many cases illustrating the 
high within-groups variability. Data is presented as luminescence (LCU) per minute (min) per DNA in 
nanograms. 
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4.4 LIVER TISSUE PRESERVES BETTER THAN SIGLE HEPATOCYTES 
Data in (paper IV) suggested that cold storage of liver samples as a tissue is superior to 
preserving them as single hepatocytes. 
 
4.4.1 Viability of Hepatocytes  
Cellular viability evaluated by trypan blue exclusion method was higher in UW tissue 
cells compared to UW cells favoring tissue preservation (figure 4.9). 
 
4.4.2 Apoptosis of Hepatocytes  
Results from apoptosis analysis were also in favor of UW tissue cells. Apoptosis rates 
were similar between fresh and preserved tissues. However, a significant increase in 
apoptosis rate was noticed in UW cells compared to fresh and preserved tissues and 
UW tissue cells. This was reflected by significantly higher numbers of TUNEL positive 
hepatocytes as well as significantly higher caspase activity in UW cells (figure 4.9). 
 
4.4.3 Plating Efficiency 
The ability of the hepatocytes to adhere to the culture dish was significantly lower in 
UW cells compared to the other groups, while it was not significantly different between 
fresh and UW tissue cells (figure 4.10). 
 
4.4.4 Activity of Drug Metabolizing Enzymes  
CYPs activity was not significantly different between UW cells and UW tissue cells, 
although there was a tendency for activity to be lower in UW cells and to be similar 
between fresh and UW tissue cells (figure 4.10). CYPs activity was successfully 
induced in culture, where RIF induced CYP3A4 more than PB (figure 4.11).  
Similarly, EROD, resorufin and ammonia assays did not favor UW tissue cells over 
UW cells (figure 4.11).  
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Figure 4.9: (A) Hepatocyte viability, (B) TUNEL staining and (C) Caspase 3/7 activity for 
hepatocytes directly after isolation (fresh), after storage of single hepatocytes in UW (UW cells), 
and after repeated hepatocyte isolation (UW tissue cells). (D) TUNEL staining was also performed 
on liver tissue obtained directly after procurement (Fresh) and after storage of liver tissue for 48h in 
UW (UW tissue). Bars show mean and standard error.  
Figure 4.10: (A) Plating efficiency and Cytochrome P450 activity for (B) CYP1A2, (C) CYP2C9, 
(D) CYP3A4 for hepatocytes directly after isolation (fresh), after storage of single hepatocytes in 
UW (UW cells), and after repeated hepatocyte isolation (UW tissue cells). CYPs activities were 
measured by luciferin-derived luminescent substrates. Bars show mean and standard error. 
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Figure 4.11: (A) EROD, (B) CYP3A4, (C) Resorufin, and (D) ammonia assays for hepatocytes 
directly after isolation (fresh), after storage of single hepatocytes in UW (UW cells), and after 
repeated hepatocyte isolation (UW tissue cells). Enzyme induction for 72hr was done by β-
Naphthoflavone (BNF) (CYP1A1/2) and Rifampicin (Rif) and Phenobarbital (PB) (CYP3A4). 
Resorufin and ammonia assays were done in suspension and after 5 days in culture. Bars show mean 
and standard error. 
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5 GENERAL DISCUSSION 
 
5.1 NEED FOR CELLULAR THERAPY FOR LIVER DISEASE 
Liver disease is a major health problem accounting for 4.4% of all deaths worldwide 
(Mathers, Lopez et al. 2006). In comparison to many other body organs, the liver is 
imparted a phenomenal capacity to regenerate. It is mainly the fully differentiated liver 
cells that are responsible for liver regeneration and its mass restoration. However, a role 
for hepatic and non-hepatic stem cells is strongly supported (Furuyama, Kawaguchi et 
al. 2011). Unfortunately, liver regeneration is not endless and becomes defective in 
end-stage liver disease. Hepatocytes lose their regenerative capacity in cirrhosis, 
obesity and NASH (Farrell, Robertson et al. 2002; Lin, Lim et al. 2010). 
The main treatment options available for end-stage liver disease are; orthotopic liver 
transplantation (OLT), hepatocyte transplantation (HT) and extracorporeal liver support 
systems. OLT has many limitations, the most serious of which is the unavailability of 
organ donors with up to 10% of patients dying in the waiting list (Strom and Ellis 
2011). HT, despite its promising results, is still an experimental treatment option. 
Although it makes it possible for other sources of hepatocytes such as porcine and 
immortalized hepatocytes to be used, human hepatocytes are the most frequent cell type 
successfully used. Similar to HT, extracorporeal support systems are still under 
extensive investigation and depend mainly on human hepatocytes in their function. 
Stem cells carry a great hope for liver disease patients as they carry the potentiality not 
only to differentiate to hepatocytes but also to support hepatocyte function when co-
transplanted with them (Gomez-Aristizabal, Keating et al. 2009; Synnergren, Heins et 
al. 2010; Chen, Tseng et al. 2012) (table 5.1). Cellular replacement therapy for liver 
disease theoretically applies the same basic principles as those for HT when it comes to 
cell numbers needed, injection sites, mechanism of action, tissue integration and 
support of liver function. Stem cells are superior to hepatocytes in terms of their high 
proliferative potential, self-renewal capacity and high differentiation potential, not only 
to hepatocytes but also to other liver cell types in vitro (Cardinale, Wang et al. 2011). 
This has raised our interest as well as others in improving stem cell differentiation to 
hepatocytes and studying the potential supportive role for MSC co-transplantation with 
hepatocytes. 
 
5.2 CHOICE BETWEEN DIFFERENT STEM CELL GROUPS  
An ideal stem cell population for liver replacement therapy has not been identified yet. 
Pluripotent stem cells such as human ESCs and iPSCs have tremendous proliferation 
and differentiation potentials compared to multipotent stem cells such as MSCs. 
Pluripotency, on the other hand, needs lots of adjustments in culturing conditions and 
differentiation protocols to maintain and precisely direct pluripotent stem cells towards 
a specific cell fate in vitro (Suwinska and Ciemerych 2011). iPSCs need more effort, 
compared to ESCs, in terms of safe and effective pluripotency induction. On the other 
hand, iPSCs are superior to ESCs when it comes to ethical and immune rejection 
issues. With iPSCs, pluripotent cells can be created from patient’s own cells and then 
used as patient-specific cellular replacement therapy. It is known that iPSCs keep the 
same human leukocyte antigen (HLA) genotype of their parental somatic cells (Masaki, 
 42 
Table 5.1: Clinical use of autologous stem/progenitor cells in liver disease. BM: bone marrow, MNCs: 
mononuclear cells, MSCs: mesenchymal stem cells, PB: peripheral blood, CD34+Cs: CD34 positive cells, 
G-CSF: granulocyte-colony stimulating factor, CP: Child-Pugh, MELD: model of end stage liver disease, 
INR: international normalized ratio, CT: computerized tomography, AFP: α-fetoprotein
Ishikawa et al. 2007), in addition to having similar proliferation and differentiation 
potentials as ESCs (Ishikawa, Banas et al. 2012). However, it has been shown recently 
that iPSCs can induce immune response in syngeneic recipients due to abnormal gene 
expression in some differentiated iPSCs. This points out the importance of evaluating 
the immunogenicity of patient’s own iPSCs before any clinical use (Zhao, Zhang et al. 
2011).  
 
Cell type Methods Outcome Reference 
BM-MNCs Peripheral vein infusion of fresh 
cells with 6 months follow up  
Significant improvement in 
albumin and protein levels and 
CP scores 
(Terai, 
Ishikawa et al. 
2006) 
 Hepatic artery infusion of fresh 
cells with 1 year follow up 
Variable effect on CP score (Lyra, Soares 
et al. 2010) 
 Peripheral vein infusion of fresh 
cells with 6 months follow up 
Improvement of CP score (Kim, Park et 
al. 2010) 
 Intrasplenic/intrahepatic injection 
of differentiated hepatocyte-like 
cells with 6 months follow up 
Significant improvement in 
albumin and protein levels, ascitis 
and CP and MELD scores 
(Amer, El-
Sayed et al. 
2011) 
BM-MSCs Peripheral/portal vein infusion of 
culture-expanded cells with 6 
months follow up 
Improvement of albumin, 
creatinine, bilirubin and INR 
levels and MELD score 
(Kharaziha, 
Hellstrom et 
al. 2009) 
PB-CD34+Cs 
(G-CSF 
mobilized) 
Hepatic artery/portal vein 
infusion of fresh cells with 2 
months follow up 
Improvement of albumin and 
bilirubin levels 
(Gordon, 
Levicar et al. 
2006) 
 Hepatic artery/portal vein 
infusion of fresh cells with 12-18 
months follow up 
Improvement of bilirubin levels, 
no tumor formation upon CT 
scanning and AFP monitoring 
(Levicar, Pai 
et al. 2008) 
 Hepatic artery infusion of fresh 
cells with 3 months follow up 
Improvement of CP score, and 
bilirubin and liver enzymes levels 
(Pai, 
Zacharoulis et 
al. 2008) 
 Hepatic artery/portal vein 
infusion of expanded and 
differentiated cells with 12 
months follow up 
20% mortality, improvement of 
bilirubin, albumin, INR and liver 
enzymes levels 
(Salama, 
Zekri et al. 
2010) 
PB-MNCs 
(G-CSF 
mobilized) 
Hepatic artery infusion with 6 
months follow up 
Improvement of CP score, and 
serum albumin, no effect on 
bilirubin and liver enzymes levels 
(Han, Yan et 
al. 2008) 
 
 
This is why we are interested in the optimization of stem cell differentiation to 
hepatocytes and the unraveling of potential roles for miRNAs in hepatocyte 
development. 
MSCs showed their potential, albeit controversial, ability to differentiate to hepatocytes 
both in vitro and in vivo (Sato, Araki et al. 2005; Aurich, Sgodda et al. 2009). Our in 
vivo preliminary work showed similar, albeit weak, evidence for successful hFL-MSC 
homing, integration and differentiation to hepatocyte-like cells in mouse liver. On the 
other hand, our efforts to differentiate hFL-MSCs in vitro (paper I) did not show a 
convincing evidence for MSC differentiation to functional hepatocytes. Our data are 
supported by reports concluding that there is no strong evidence for MSC 
differentiation to hepatocyte-like cells with a broad range of mature hepatocyte 
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functions (Strom and Ellis 2011; Ishikawa, Banas et al. 2012) debating true MSC trans-
differentiation towards hepatic lineages (Gurudutta, Satija et al. 2012). 
There is a growing evidence for other important contributions that MSCs might add to 
the field of liver cellular therapy apart from their possible trans-differentiation to 
hepatocytes. These contributions are mainly related to MSC paracrine functions rather 
than a direct role in liver regeneration. Allogeneic MSC transplantation has been 
suggested to support hepatocyte survival, proliferation and function both in vivo and in 
vitro and to decrease the host allogeneic response to transplanted hepatocytes and 
modulate stellate cell activation in liver cirrhosis causing its regression (Isoda, Kojima 
et al. 2004; Gomez-Aristizabal, Keating et al. 2009). Promising phase I/II clinical trials 
strongly support the use of MSCs in patients with decompensated liver cirrhosis 
(Mohamadnejad, Alimoghaddam et al. 2007; Kharaziha, Hellstrom et al. 2009; Zhang, 
Lin et al. 2012) and liver failure (Amer, El-Sayed et al. 2011). In paper I, hFL-MSCs 
isolated by means of CD271 selection proved to be non-immunogenic and 
immunomodulatory. An immunomodulatory effect by MSCs isolated from human fetal 
liver can be predicted also from their ability to inhibit lymphocyte proliferation induced 
by mitogens (Gotherstrom, Ringden et al. 2003). The immunomodulatory 
characteristics of MSCs may have therapeutic effects. For example, MSCs showed their 
ability to enhance tissue repair, probably through promoting survival and proliferation 
of endogenous cells, inducing angiogenesis, inhibiting inflammatory and immune 
responses and reducing apoptosis (Lee, Oh et al. 2011). The inhibitory effect of hFL-
MSCs, shown in paper I, on lymphocyte allogeneic responses in co-cultures of 
lymphocytes and HepG2 cells, suggests their potential immunosuppressive role in 
hepatocyte co-transplantation. 
 
5.3 DIFFERENTIATION PROTOCOLS 
5.3.1 Cytokine-based Protocols 
The core principle in any stem cell differentiation protocol is to emulate the natural in 
vivo scenario of development. Many cell types have been tested for their differentiation 
potential to hepatocytes; the most prominent of them were hematopoietic stem cells 
(Almeida-Porada, Zanjani et al. 2010), MSCs (Aurich, Sgodda et al. 2009), ESCs 
(Synnergren, Heins et al. 2010) and iPSCs (Chen, Tseng et al. 2012). There are several 
published protocols tailored for each specific stem cell type. These protocols employ 
treating stem cells mainly with cytokine cocktails, but sometimes with conditioning 
media (Chen, Dong et al. 2007), or co-culturing them with liver non-parenchymal cells 
(Soto-Gutierrez, Navarro-Alvarez et al. 2007; Deng, Chen et al. 2008). Although, a 
combination of all these methods seems to be closer to the natural scenario, it is 
generally recommended to use a clearly defined differentiation protocol. 
Much information is still lacking about hepatocyte development in vivo. The possibility 
for the presence of unidentified compensatory developmental pathways for other well-
known pathways cannot be excluded (Gallitzendoerfer, Abouzied et al. 2008). Also, the 
concept of redundancy of certain growth factors or pathways raises the question of 
functional redundancy versus functional interaction (Fassler and Meyer 1995; Miller, 
Ortega et al. 2000).  
The current differentiation protocols employ mainly culture conditions, which are quite 
far from the natural three-dimensional niche for developing endodermal and hepatic 
cells. Mutual interaction between hepatoblasts and surrounding mesodermal cells 
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(Margagliotti, Clotman et al. 2008), endothelial cells (Matsumoto, Yoshitomi et al. 
2001) and septum transversum (Rossi, Dunn et al. 2001) seems to be crucial for normal 
hepatic development. Developing liver cells migrates freely and the relationship 
between them and the surrounding cells is dynamic with continuous change in the 
spatial relationship between the cells, which in turn creates a continuous change in 
effecting cytokine combination and their concentrations (Serls, Doherty et al. 2005). 
Promising three-dimensional differentiation considering the above-mentioned facts 
have been done but still need further optimization (Ring, Gerlach et al. 2010; Miki, 
Ring et al. 2011). 
Extracellular matrix composition is crucial for proper liver development. Several 
important components have been identified during liver development (Shiojiri and 
Sugiyama 2004). Several materials have been used in vitro with new factors 
continuously added to the list aiming at simulating the in vivo architecture. Using 
natural and synthetic biomaterials for maintaining hepatocyte functions is gaining more 
interest nowadays (Soto-Gutierrez, Kobayashi et al. 2006) and whether this will be 
successfully applied in stem cell differentiation in vitro still needs further evaluation 
(Soto-Gutierrez, Navarro-Alvarez et al. 2006). 
Stem cell death during in vitro hepatocyte differentiation may occur and it is usually 
attributed to selection of cells with higher commitment to the hepatic fate. However, 
there might be another explanation for this when putting it into the context of the in 
vivo scenario. It has been shown that for their survival, hepatoblasts need to be 
protected against apoptosis during development (Doi, Marino et al. 1999; Piazzolla, 
Meissl et al. 2005). Whether this should be applied in the in vitro protocols needs 
further investigation. 
The length of a given in vitro differentiation protocol is always an issue, and the target 
is always to keep it short and simple. Most of the hepatocyte differentiation protocols 
begin with stimulating stem cells to differentiate to definitive endoderm first, passing to 
hepatocyte induction and ending with hepatocyte maturation; all within few weeks. 
Comparing this to the in vivo liver development, we know that it takes several months 
with the maturation itself extending even to the postnatal period (Kelley-Loughnane, 
Sabla et al. 2002). This fact raises the question of how realistic it is to obtain fully 
mature stem cell-derived hepatocytes in vitro within a relatively short period. 
The differentiation protocol used here was previously used elsewhere to differentiate 
adult MSCs to hepatocytes (Campard, Lysy et al. 2008; Lysy, Smets et al. 2008). 
Although our stimulated hFL-MSCs showed some similarities to what is stated in these 
protocols, they did not express any hepatocyte-specific CYP activity. Whether it is cell 
line dependent or that the protocol needs further optimization requires further 
evaluation. The challenge still facing the field of stem cell differentiation to hepatocytes 
is not only to generate fully mature hepatic cells, but also to try to arrange them in a 
three-dimensional architecture forming a bioartificial liver implant. 
 
5.3.2 miRNA-based Differentiation 
The miR-290 cluster is abundantly expressed in ESCs representing up to 70% of all 
miRNAs in undifferentiated mouse ESCs (Marson, Levine et al. 2008). The hsa-miR-
372 is orthologous to the mouse miR-294 (Subramanyam, Lamouille et al. 2011), and 
members of this cluster are mostly involved in the regulation of cell cycle, especially in 
ESCs (Marson, Levine et al. 2008). Growing evidence strongly suggests the 
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involvement of miRNAs not only in maintaining ESC pluripotency but also in guiding 
their differentiation. miRNAs are upregulated after the induction of ESC differentiation 
to reduce the expression of pluripotency markers and promote differentiation. It has 
been shown that miR-296 represses Nanog (Tay, Zhang et al. 2008), while miR-145 
represses Oct4, Sox2 and Klf4 (Xu, Papagiannakopoulos et al. 2009). Similarly, miR-
134 and miR-470 target Nanog, Oct4 and Sox2 (Tay, Zhang et al. 2008) and miR-200c, 
miR-203 and miR-183 repress Sox2 and Klf4 (Wellner, Schubert et al. 2009). 
In addition, miRNAs showed their ability to induce cellular reprogramming. 
Reprogramming of human fibroblasts was promoted by overexpression of miR-302 
cluster and miR-372 together with using Oct3/4, Sox2, c-Myc and Klf4 (Subramanyam, 
Lamouille et al. 2011). Quite interestingly, overexpression of the miR-302 cluster 
together with miR-367 successfully reprogrammed mouse and human somatic cells in 
the absence of other factors in a way that was more rapid and efficient than classical 
reprogramming using Oct3/4, Sox2, c-Myc and Klf4 (Anokye-Danso, Trivedi et al. 
2011). It is not clearly understood how miRNA overexpression promotes or induces 
reprogramming, but targeting regulators of cell cycle, cell epigenetics or epithelial-
mesenchymal transition such as TGFβ pathway could be an explanation 
(Subramanyam, Lamouille et al. 2011). In addition to the overexpression of ESC-
enriched miRNAs, reduced expression of miRNAs enriched in differentiated cells 
seemed to enhance reprogramming (Yang, Li et al. 2011) possibly through reducing 
P53 expression (Choi, Lin et al. 2011). Reprogramming using miRNAs appears to be 
more rapid, efficient and safer than vector-based reprogramming. Whether this 
approach can be used similarly to create hepatocyte-derived iPSCs needs extensive 
research. 
In addition to their use in pluripotency induction, miRNAs showed ability to induce 
differentiation. For example, the overexpression of miR-499 induced myocyte 
differentiation of cardiac stem/progenitor cells both in vitro (Sluijter, van Mil et al. 
2010) and in vivo (Hosoda, Zheng et al. 2011). A potential role for miRNAs during 
liver development and regeneration has been suggested. More than 40 miRNAs have 
been identified so far in human liver (Liu, Fan et al. 2010) and their expression patterns 
were similar to those for ESC-derived hepatocyte-like cells (Kim, Kim et al. 2011). 
There is evidence for a role of miRNAs during liver development (Hand, Master et al. 
2009; Rogler, Levoci et al. 2009), and it has been shown that promoters of several 
liver-enriched miRNAs have putative binding sites for the liver-enriched transcription 
factors (LETFs) HNF4α and FoxA2 (Gao, Schug et al. 2011). For example, the 
expression levels for miR-122, the most abundant miRNA in the liver, positively 
correlate with those for LETFs in hepatocarcinoma cell lines (Chang, Nicolas et al. 
2004). Moreover, the promotor of miR-122 was stimulated by FoxA2, HNF1α, HNF4α 
and C/EBPα (Xu, He et al. 2010). Quite recently, it has been shown that miR-122 
induced the expression of hepatocyte-specific genes and several LETFs, including 
HNF4α, suggesting the presence of a positive feedback loop formed by miR-122 and 
HNF4α directing hepatocyte differentiation (Laudadio, Manfroid et al. 2012). 
Extensive research is still needed to determine whether miR-122, and other liver-
specific miRNAs, can be the first building blocks in a miRNA-based differentiation 
protocol for hepatocytes. 
Our work in paper II, together with others, constitutes the first steps towards the 
identification of liver-specific miRNAs. We managed to profile miRNAs expressed in 
human fetal and adult livers. Worthy of mentioning is that miR-122 was not 
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significantly expressed in our microarray data for no apparent reasons. We could link 
identified miRNAs bioinformatically to many physiological processes related to liver 
development. However, lots of work is still needed to identify precisely any potential 
role for individual miRNAs in liver development and the possibility of benefitting from 
them in stem cell differentiation towards hepatic lineages. 
 
5.4 OBSTACLES TO LIVER CELLULAR THERAPY 
5.4.1 Differentiation Efficiency 
The main goal for stem cell differentiation towards hepatic lineages is to use the 
derived hepatocyte-like cells clinically. A given differentiation protocol should be 
efficient in terms of both quantity and quality. In order to replace 10-20% of human 
liver mass, around 1010 cells would be required (Dan 2012) and the differentiation 
protocol must result in pure and homogeneous cell population. Characterization should 
not only focus on expression of hepatic markers on the gene and protein levels, but 
more on thorough functional evaluation. Functional assessment should focus not only 
on albumin secretion and CYPs activity, but also on other important hepatic functions 
such as clotting factor synthesis, detoxification, ammonia metabolism and bilirubin 
excretion. 
In our differentiation experiments, we focused mainly on CYPs activity and not so 
much on detection of hepatic markers to evaluate the maturity of differentiated stem 
cells. So far, no convincing evidence supports the presence of real stem cell-derived 
hepatocytes and further optimization is still needed for the differentiation protocols 
(Strom and Ellis 2011; Dan 2012; Ishikawa, Banas et al. 2012). Lots of efforts are still 
needed to improve the MSC (and ESC/iPSC) differentiation protocols. As we have 
shown in paper I, it may be possible to co-transplant hFL-MSCs directly without 
differentiation with hepatocytes to support their survival and function and possibly 
ameliorate host immune response against them. 
 
5.4.2 Safety 
Tumor formation is one of the biggest concerns regarding pluripotent stem cell therapy. 
Also, using multipotent stem cells is not without risk. It has been shown that only one 
undifferentiated ESC is sufficient to form a teratoma upon transplantation (Ishii, 
Yasuchika et al. 2007) where uncontrolled replication or epithelial-mesenchymal 
transition could be possible explanations. Scaling-up and differentiation of stem cells is 
critical where cells might transform or precipitate genetic mutations. Thus, safety tests 
need to be carried out before using stem cells for transplantation. Also, stem cells must 
be cultured under good manufacturing practice (GMP) criteria and xeno-free culturing 
systems should be applied. Furthermore, the use of immunosuppression carries risk of 
infection among others. Using autologous iPSCs/MSCs and immune inert MSCs could 
be useful in this context. 
 
5.4.3 Transplantation, Homing and Repopulation 
Cell transplantation can be performed through a catheter introduced into the portal vein, 
hepatic artery or splenic artery (Puppi and Dhawan 2009). Bleeding, thrombosis, 
infection and portal hypertension are potential risks (Gagandeep, Rajvanshi et al. 2000). 
No convincing data support one route to be ideal for transplantation. For hFL-MSC 
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transplantation, we used the spleen in mouse for technical feasibility. Homing signals, 
such as stem cell factor, have been reported to help stem cells to home into the liver in 
animal studies (Hatch, Zheng et al. 2002). Whether this can be enough for stem cell 
homing to human liver, still needs further assessment. Hepatocyte engraftment is not 
usually more than 30% (Chandan Guha, S. S. G. et al.), which might explain the fewer 
number of the human hepatocyte-like cells seen in the mouse liver in our preliminary 
data. Luckily, a repopulation of 1-5% was enough to correct, at least transiently, liver 
functional defects functioning as a bridge to OLT (Fox, Chowdhury et al. 1998; 
Hughes, Mitry et al. 2012). Functional improvement was only temporary probably due 
to low engraftment, low replicative pressure and cell loss during injection. 
Repopulation can be improved probably by preconditioning of the liver e.g. by left lobe 
embolization, partial hepatectomy and radiation or chemical liver injury (Dan 2012). 
Co-transplantation with other supportive cell types such as MSCs might help improve 
engraftment and repopulation as well as modulate host immune response (Isoda, 
Kojima et al. 2004; Gomez-Aristizabal, Keating et al. 2009). Our preliminary data of 
hFL-MSC transplantation into mice suggested the possibility of hFL-MSCs to 
differentiate to hepatocyte-like cells within the host liver. Adding to this the 
immunomodulatory effects that hFL-MSCs showed in paper I, our next step will be to 
co-transplant hFL-MSCs and hepatocytes in an animal model.  
 
5.4.4 Cryopreservation and Cold Storage 
Preservation of primary human hepatocytes and stem cell-derived hepatocyte-like cells 
necessitates the presence of a fully optimized cryopreservation protocol. To date, there 
is no fully optimized cryopreservation protocol available. Several protocols have been 
published with promising results (Rijntjes, Moshage et al. 1986; Dou, de Sousa et al. 
1992; Li, Lu et al. 1999; Alexandre, Viollon-Abadie et al. 2002; Hewitt 2010; Terry, 
Dhawan et al. 2010), but much improvement can still be done such as hepatocyte pre-
incubation with anti-oxidants prior to cryopreservation or including non-permeating 
cryoprotectants in the freezing solution (Stephenne, Najimi et al. 2010). In paper III, we 
introduced a new experimentally optimized xeno-free cryoprotectant medium (CB) to 
the field of hepatocyte cryopreservation. Compared to the standard protocol (DMSO-
UW), CB contained not only DMSO but also a non-permeating cryoprotectant at 
carefully tested concentrations (Holm, Strom et al. 2010), which better preserved 
hepatocyte viability.  
During hepatocyte transplantation, only 5% of the liver mass can be infused at one 
transplantation event. Cell infusion has to be distributed over hours or days to avoid the 
risk of portal thrombosis (Fox, Chowdhury et al. 1998). Thus, repeated transplantations 
are necessary to obtain adequate engraftment. As a result, hepatocytes are needed to be 
cold stored between repeated infusions (Fox, Chowdhury et al. 1998; Stephenne 2006; 
Fox, Soltys et al. 2011). However, cold storage is not fully optimized with inevitable 
hepatocyte necrosis and apoptosis (Smets, Chen et al. 2002; Abrahamse, van Runnard 
Heimel et al. 2003; Gomez-Lechon, Lahoz et al. 2008; Pless, Sauer et al. 2011; Pless-
Petig, Singer et al. 2012). Anoikis, a newly described form of apoptosis, affects mainly 
cells lacking cell anchorage and starts as early as 15 minutes after hepatocyte isolation 
(Smets, Chen et al. 2002). This raised our interest in comparing cold storage of liver 
samples as single hepatocytes versus intact tissue. Our data in paper IV strongly 
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supported tissue preservation against single cell preservation. However, transplantation 
experiments using animal models will add to our knowledge in this respect. 
 
5.4.5 Functional Evaluation 
Evaluating the function of hepatocytes or hepatocyte-like cells before transplantation to 
liver patients is of paramount importance. Preserving hepatocyte function is a 
determining factor during the evaluation of a given cryopreservation/cold storage 
protocol. The high variability between one liver sample and another usually makes it 
difficult to define the ‘normal liver’. There are many reasons for variability, such as 
genetic polymorphism, gene expression modulation, tissue quality, and tissue handling 
before and during hepatocyte isolation (Klieber, Torreilles et al. 2010). Hepatocytes 
vary dramatically in drug-metabolizing enzyme (DME) activity between different 
samples as noticed from our papers III and IV. This argues against DME sensitivity in 
favoring one cell sample over the other. This was in line with what others reported 
where there were no significant differences between fresh and cryopreserved 
hepatocytes regarding DME activities (Li, Lu et al. 1999). However, cell viability and 
plating efficiency may be more sensitive. Plating efficiency refers to the ability of the 
cells to attach themselves to the culture dish and requires intact cell adhesion molecules 
(Terry, Hughes et al. 2007), and it is suggested to be a marker for engraftment ability 
and thus is an important quality to maintain (Gramignoli, Green et al. 2011). In (paper 
IV), we tested the hepatocytes for the plating efficiency, CYPs activity, ammonia 
metabolism as well as phase-II metabolism. 
   49 
6 CONCLUSIONS AND FUTURE PERSPECTIVES 
 
 Human fetal liver contains a mesenchymal stem cell population. The hepatic 
origin, mesenchymal nature and immunomodulatory properties of these cells 
suggest them as a candidate for cellular replacement therapy for liver disease 
mainly for their immunomodulatory and supportive properties when co-
transplanted with hepatocytes. However, further work is still needed to evaluate 
the safety, homing, engraftment, survival and function of such cells upon 
transplantation. When transplanting them into nude mice, we were able to 
identify human hepatocyte-like cells within mouse liver, but this still needs 
further evaluation. 
 The human liver expresses a wide range of microRNAs, of which many have 
been linked to liver development. However, functional studies are still needed 
to verify the specific roles that individual microRNAs account for in liver 
development and the possibility of their use in microRNA-based stem cell 
differentiation protocols. 
 A new xeno-free cryopreservation medium has been introduced to the field of 
hepatocyte cryopreservation. The new medium still needs to be tested in 
experimental animals. 
 Cold storage of liver samples as tissue seemed to preserve hepatocyte viability 
and function better than when preserved as single cells. Further in vivo 
transplantation of preserved tissue hepatocytes is still needed to confirm their 
better survival and functionality. 
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